Document and Entity Information
Document and Entity Information - shares | 9 Months Ended | |
Sep. 30, 2019 | Nov. 15, 2019 | |
Document And Entity Information | ||
Entity Registrant Name | RespireRx Pharmaceuticals Inc. | |
Entity Central Index Key | 0000849636 | |
Document Type | 10-Q | |
Document Period End Date | Sep. 30, 2019 | |
Amendment Flag | false | |
Current Fiscal Year End Date | --12-31 | |
Entity Reporting Status Current | Yes | |
Entity Interactive Data Current | Yes | |
Entity Filer Category | Non-accelerated Filer | |
Entity Small Business Flag | true | |
Entity Emerging Growth Company | false | |
Entity Ex Transition Period | false | |
Entity Shell Company | false | |
Entity Common Stock, Shares Outstanding | 4,045,073 | |
Document Fiscal Period Focus | Q3 | |
Document Fiscal Year Focus | 2019 |
Condensed Consolidated Balance
Condensed Consolidated Balance Sheets - USD ($) | Sep. 30, 2019 | Dec. 31, 2018 |
Current assets: | ||
Cash and cash equivalents | $ 94 | $ 33,284 |
Advance payment on research contract | 48,912 | 48,912 |
Prepaid expenses | 57,737 | 38,880 |
Total current assets | 106,743 | 121,076 |
Long-term prepaid insurance | 3,114 | |
Total assets | 106,743 | 124,190 |
Current liabilities: | ||
Accounts payable and accrued expenses, including $536,100 and $400,229 payable to related parties at September 30, 2019 and December 31, 2018, respectively | 3,729,199 | 3,296,620 |
Accrued compensation and related expenses | 1,890,334 | 1,304,434 |
Convertible notes payable including accrued interest of $95,425 and $62,635 at September 30, 2019 and December 31, 2018, respectively ($42,406 and $38,292, including accrued interest of $17,406 and $13,292, was deemed to be in default at September 30, 2019 and December 31, 2018, respectively and net of $104,858 and $27,969 of amortized debt discounts at September 30, 2019 and December 31, 2018, respectively (Note 4)) | 469,067 | 239,666 |
Note payable to SY Corporation (as defined below), including accrued interest of $351,189 and $315,307 at September 30, 2019 and December 31, 2018, respectively (payment obligation currently in default - Note 4) | 723,187 | 744,441 |
Notes payable to officers, including accrued interest of $32,799 and $25,116 as of September 30, 2019 and December 31, 2018, respectively (Note 4) | 140,649 | 109,216 |
Notes payable to former officer, including accrued interest of $38,091 and $26,561 as of September 30, 2019 and December 31, 2018, respectively (Note 4) | 165,691 | 154,161 |
Other short-term notes payable | 27,997 | 8,907 |
Total current liabilities | 7,146,124 | 5,857,445 |
Commitments and contingencies (Note 8) | ||
Stockholders' deficiency: (Note 6) | ||
Series B convertible preferred stock, $0.001 par value; $0.6667 per share liquidation preference; aggregate liquidation preference $25,001; shares authorized: 37,500; shares issued and outstanding: 11; common shares issuable upon conversion at 0.00030 common shares per Series B share | 21,703 | 21,703 |
Common stock, $0.001 par value; shares authorized: 65,000,000; shares issued and outstanding: 3,879,576 and 3,872,076 at September 30, 2019 and December 31, 2018, respectively | 3,880 | 3,872 |
Additional paid-in capital | 158,816,477 | 158,635,222 |
Accumulated deficit | (165,881,441) | (164,394,052) |
Total stockholders' deficiency | (7,039,381) | (5,733,255) |
Total liabilities and stockholders' deficiency | $ 106,743 | $ 124,190 |
Condensed Consolidated Balanc_2
Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) | Sep. 30, 2019 | Dec. 31, 2018 |
Accounts payable and accrued expenses to related party | $ 536,100 | $ 400,229 |
Accrued interest | 17,406 | 13,292 |
Notes default amount | 42,406 | 38,292 |
Debt discount | $ 104,858 | $ 27,969 |
Preferred stock, par value | $ 0.001 | |
Preferred stock, shares authorized | 5,000,000 | |
Common stock, par value | $ 0.001 | $ 0.001 |
Common stock, shares authorized | 65,000,000 | 65,000,000 |
Common stock, shares issued | 3,879,576 | 3,872,076 |
Common stock, shares outstanding | 3,879,576 | 3,872,076 |
Officers [Member] | ||
Accrued interest | $ 32,799 | $ 25,116 |
Former Officers [Member] | ||
Accrued interest | 38,091 | 26,561 |
SY Corporation [Member] | ||
Accrued interest | 351,189 | 315,307 |
Convertible Notes Payable [Member] | ||
Accrued interest | $ 95,425 | $ 62,635 |
Series B Convertible Preferred Stock [Member] | ||
Preferred stock, par value | $ 0.001 | $ 0.001 |
Preferred stock, liquidation preference, per share | $ 0.6667 | $ 0.6667 |
Preferred stock, liquidation preference value | $ 25,001 | $ 25,001 |
Preferred stock, shares authorized | 37,500 | 37,500 |
Preferred stock, shares issued | 11 | 11 |
Preferred stock, shares outstanding | 11 | 11 |
Preferred stock shares issuable upon conversion, per share | $ 0.00030 | $ 0.00030 |
Condensed Consolidated Statemen
Condensed Consolidated Statements of Operations (Unaudited) - USD ($) | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2019 | Sep. 30, 2018 | Sep. 30, 2019 | Sep. 30, 2018 | |
Operating expenses: | ||||
General and administrative, including $121,600 and $204,383 to related parties for the three months ended September 30, 2019 and 2018, respectively, and $364,825 and $1,671,765 to related parties for the nine months ended September 30, 2019 and 2018, respectively | $ 279,930 | $ 350,561 | $ 874,834 | $ 1,138,336 |
Research and development, including $122,400 to related parties for the three months ended September 30, 2019 and 2018, and $367,200 and $367,613 to related parties for the nine months ended September 30, 2019 and 2018, respectively | 150,527 | 153,035 | 447,877 | 458,262 |
Total operating expenses | 430,457 | 503,596 | 1,322,711 | 1,596,598 |
Loss from operations | (430,457) | (503,596) | (1,322,711) | (1,596,598) |
Loss on extinguishment of debt and other liabilities in exchange for equity | (116,407) | |||
Interest expense, including $2,589 and $11,714 to related parties for the three months ended September 30, 2019 and 2018, respectively, and $7,683 and $29,937 to related parties for the nine months ended September 30, 2019 and 2018, respectively | (70,168) | (35,161) | (221,813) | (96,230) |
Foreign currency transaction gain (loss) | 30,781 | 2,983 | 57,135 | (108,582) |
Net loss attributable to common stockholders | $ (469,844) | $ (535,774) | $ (1,487,389) | $ (1,917,817) |
Net loss per common share - basic and diluted | $ (0.12) | $ (0.16) | $ (0.38) | $ (0.59) |
Weighted average common shares outstanding - basic and diluted | 3,874,465 | 3,398,940 | 3,873,097 | 3,228,528 |
Condensed Consolidated Statem_2
Condensed Consolidated Statements of Operations (Unaudited) (Parenthetical) - USD ($) | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2019 | Sep. 30, 2018 | Sep. 30, 2019 | Sep. 30, 2018 | |
Income Statement [Abstract] | ||||
General and administrative expense to related parties | $ 121,600 | $ 204,383 | $ 364,825 | $ 1,671,765 |
Research and development expenses to related parties | 122,400 | 122,400 | 367,200 | 367,613 |
Interest expense to related parties | $ 2,589 | $ 11,714 | $ 7,683 | $ 29,937 |
Condensed Consolidated Statem_3
Condensed Consolidated Statements of Stockholders' Deficiency (Unaudited) - USD ($) | 3 Months Ended | 9 Months Ended | 12 Months Ended | ||||||
Sep. 30, 2019 | Jun. 30, 2019 | Mar. 31, 2019 | Sep. 30, 2018 | Jun. 30, 2018 | Mar. 31, 2018 | Sep. 30, 2019 | Sep. 30, 2018 | Dec. 31, 2018 | |
Series B Convertible Preferred Stock [Member] | |||||||||
Balance beginning | $ 21,703 | $ 21,703 | $ 21,703 | $ 21,703 | $ 21,703 | $ 21,703 | $ 21,703 | $ 21,703 | $ 21,703 |
Balance beginning, shares | 37,500 | 37,500 | 37,500 | 37,500 | 37,500 | 37,500 | 37,500 | 37,500 | 37,500 |
Fair value of common stock warrants issued in connection with convertible notes | |||||||||
Fair value of common stock warrants and beneficial conversion feature associated with convertible notes | |||||||||
Sale of common stock units in private placement, net of escrow fees of $5,000 | |||||||||
Sale of common stock units in private placement, net of escrow fees of $5,000, shares | |||||||||
Issuance of common stock units in exchange for note payable to officer | |||||||||
Issuance of common stock units in exchange for note payable to officer, shares | |||||||||
Net loss | |||||||||
Balance ending | $ 21,703 | $ 21,703 | $ 21,703 | $ 21,703 | $ 21,703 | $ 21,703 | $ 21,703 | $ 21,703 | $ 21,703 |
Balance ending, shares | 37,500 | 37,500 | 37,500 | 37,500 | 37,500 | 37,500 | 37,500 | 37,500 | 37,500 |
Common Stock [Member] | |||||||||
Balance beginning | $ 3,872 | $ 3,872 | $ 3,872 | $ 3,350 | $ 3,123 | $ 3,065 | $ 3,872 | $ 3,065 | $ 3,065 |
Balance beginning, shares | 3,872,076 | 3,872,076 | 3,872,076 | 3,349,619 | 3,123,332 | 3,065,261 | 3,872,076 | 3,065,261 | 3,065,261 |
Common stock issued related to extinguishment of convertible notes | $ 227 | $ 58 | |||||||
Common stock issued related to extinguishment of convertible notes, shares | 226,287 | 58,071 | |||||||
Fair value of common stock warrants issued in connection with convertible notes | |||||||||
Fair value of common stock warrants and beneficial conversion feature associated with convertible notes | $ 8 | ||||||||
Fair value of common stock warrants and beneficial conversion feature associated with convertible notes, shares | 7,500 | ||||||||
Sale of common stock units in private placement, net of escrow fees of $5,000 | $ 190 | ||||||||
Sale of common stock units in private placement, net of escrow fees of $5,000, shares | 191,194 | ||||||||
Issuance of common stock units in exchange for note payable to officer | $ 48 | ||||||||
Issuance of common stock units in exchange for note payable to officer, shares | 47,620 | ||||||||
Net loss | |||||||||
Balance ending | $ 3,880 | $ 3,872 | $ 3,872 | $ 3,588 | $ 3,350 | $ 3,123 | $ 3,880 | $ 3,588 | $ 3,872 |
Balance ending, shares | 3,879,576 | 3,872,076 | 3,872,076 | 3,588,433 | 3,349,619 | 3,123,332 | 3,879,576 | 3,588,433 | 3,872,076 |
Additional Paid-in Capital [Member] | |||||||||
Balance beginning | $ 158,768,984 | $ 158,681,034 | $ 158,635,222 | $ 158,090,123 | $ 157,546,861 | $ 157,422,110 | $ 158,635,222 | $ 157,422,110 | $ 157,422,110 |
Fair value of common stock options issued to consultants | 335,303 | 14,474 | |||||||
Common stock issued related to extinguishment of convertible notes | 207,959 | 110,277 | |||||||
Fair value of common stock warrants issued in connection with convertible notes | 87,950 | 45,812 | |||||||
Fair value of common stock warrants and beneficial conversion feature associated with convertible notes | 47,493 | ||||||||
Sale of common stock units in private placement, net of escrow fees of $5,000 | 195,558 | ||||||||
Issuance of common stock units in exchange for note payable to officer | 49,952 | ||||||||
Net loss | |||||||||
Balance ending | 158,816,477 | 158,768,984 | 158,681,034 | 158,335,633 | 158,090,123 | 157,546,861 | 158,816,477 | 158,335,633 | 158,635,222 |
Accumulated Deficit [Member] | |||||||||
Balance beginning | (165,411,597) | (164,934,384) | (164,394,052) | (163,184,304) | (162,548,941) | (161,802,262) | (164,394,052) | (161,802,262) | (161,802,262) |
Fair value of common stock warrants issued in connection with convertible notes | |||||||||
Net loss | (469,844) | (477,213) | (540,332) | (535,774) | (635,363) | (746,679) | |||
Balance ending | (165,881,441) | (165,411,597) | (164,934,384) | (163,720,078) | (163,184,304) | (162,548,941) | (165,881,441) | (163,720,078) | (164,394,052) |
Balance beginning | (6,617,038) | (6,227,775) | (5,733,255) | (5,069,128) | (4,977,254) | (4,355,384) | (5,733,255) | (4,355,384) | (4,355,384) |
Fair value of common stock options issued to consultants | 335,303 | 14,474 | |||||||
Common stock issued related to extinguishment of convertible notes | 208,186 | 110,335 | |||||||
Fair value of common stock warrants issued in connection with convertible notes | 87,950 | 45,812 | |||||||
Fair value of common stock warrants and beneficial conversion feature associated with convertible notes | 47,501 | ||||||||
Sale of common stock units in private placement, net of escrow fees of $5,000 | 195,748 | ||||||||
Issuance of common stock units in exchange for note payable to officer | 50,000 | ||||||||
Net loss | (469,844) | (477,213) | (540,332) | (535,774) | (635,363) | (746,679) | (1,487,389) | (1,917,817) | (2,591,790) |
Balance ending | $ (7,039,381) | $ (6,617,038) | $ (6,227,775) | $ (5,359,154) | $ (5,069,128) | $ (4,977,254) | $ (7,039,381) | $ (5,359,154) | $ (5,733,255) |
Condensed Consolidated Statem_4
Condensed Consolidated Statements of Stockholders' Deficiency (Parenthetical) | Sep. 30, 2018USD ($) |
Statement of Stockholders' Equity [Abstract] | |
Escrow fees | $ 5,000 |
Condensed Consolidated Statem_5
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) | 3 Months Ended | 9 Months Ended | 12 Months Ended | ||||
Sep. 30, 2019 | Mar. 31, 2019 | Sep. 30, 2018 | Mar. 31, 2018 | Sep. 30, 2019 | Sep. 30, 2018 | Dec. 31, 2018 | |
Cash flows from operating activities: | |||||||
Net loss | $ (469,844) | $ (540,332) | $ (535,774) | $ (746,679) | $ (1,487,389) | $ (1,917,817) | $ (2,591,790) |
Adjustments to reconcile net loss to net cash used in operating activities: | |||||||
Amortization of debt discounts | 119,793 | ||||||
Amortization of debt issuance costs | 2,580 | ||||||
Loss on extinguishment of debt | 105,253 | ||||||
Loss on extinguishment of other liabilities | 11,154 | ||||||
Stock-based compensation and fees included in - General and administrative expenses | 14,248 | ||||||
Foreign currency transaction (gain) loss | (30,781) | (2,983) | (57,135) | 108,582 | |||
Changes in operating assets and liabilities: | |||||||
Prepaid expenses | (15,743) | (13,030) | |||||
Accounts payable and accrued expenses | 432,579 | 456,302 | |||||
Accrued compensation and related expenses | 585,900 | 836,849 | |||||
Accrued interest payable | 105,724 | 198,493 | |||||
Net cash used in operating activities | (313,691) | (199,966) | (427,368) | ||||
Cash flows from financing activities: | |||||||
Proceeds from sale of common stock units | 200,750 | ||||||
Placement agent and other offering fees | (5,000) | ||||||
Proceeds from convertible notes borrowings | 263,501 | ||||||
Debt issuance costs | (8,000) | ||||||
Proceeds from issuance of note payable to officer | 25,000 | ||||||
Net cash provided by financing activities | 280,501 | 195,750 | |||||
Cash and cash equivalents: | |||||||
Net decrease | (33,190) | (4,216) | |||||
Balance at beginning of period | $ 33,284 | $ 84,902 | 33,284 | 84,902 | 84,902 | ||
Balance at end of period | $ 94 | $ 80,686 | 94 | 80,686 | $ 33,284 | ||
Cash paid for - | |||||||
Interest | 4,936 | 2,802 | |||||
Non-cash financing activities: | |||||||
10% convertible notes payable, including accrued interest of $62,267, exchanged for common stock | 213,266 | ||||||
Accounts payable and accrued expenses extinguished with common stock options | 335,529 | ||||||
Officer note payable, exchanged for common stock units | 50,000 | ||||||
Issuance of common stock with 10% convertible notes | 1,588 | ||||||
Warrants issued with convertible debt | 80,698 | ||||||
Original issue discounts associated with convertible debt | $ 15,500 |
Condensed Consolidated Statem_6
Condensed Consolidated Statements of Cash Flows (Parenthetical) | 9 Months Ended |
Sep. 30, 2018USD ($) | |
Statement of Cash Flows [Abstract] | |
Convertible notes payable percentage | 10.00% |
Accrued interest | $ 62,267 |
Organization and Basis of Prese
Organization and Basis of Presentation | 9 Months Ended |
Sep. 30, 2019 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Organization and Basis of Presentation | 1. Organization and Basis of Presentation Organization RespireRx Pharmaceuticals Inc. (“RespireRx” or the “Company”) was formed in 1987 under the name Cortex Pharmaceuticals, Inc. to engage in the discovery, development and commercialization of innovative pharmaceuticals for the treatment of neurological and psychiatric disorders. On December 16, 2015, RespireRx filed a Certificate of Amendment to its Second Restated Certificate of Incorporation with the Secretary of State of the State of Delaware to amend its Second Restated Certificate of Incorporation to change its name from Cortex Pharmaceuticals, Inc. to RespireRx Pharmaceuticals Inc. While previously developing potential applications for respiratory disorders, RespireRx has retained and expanded its ampakine intellectual property and data with respect to neurological and psychiatric disorders and is considering developing certain potential products in this platform, if it is able to obtain additional financing and/or strategic relationships. In August 2012, RespireRx acquired Pier Pharmaceuticals, Inc. (“Pier”), which is now its wholly-owned subsidiary. Basis of Presentation The condensed consolidated financial statements are of RespireRx and its wholly-owned subsidiary, Pier (collectively referred to herein as the “Company,” “we” or “our,” unless the context indicates otherwise). The condensed consolidated financial statements of the Company at September 30, 2019 and for the nine months and three months ended September 30, 2019 and 2018, are unaudited. In the opinion of management, all adjustments (including normal recurring adjustments) have been made that are necessary to present fairly the condensed consolidated financial position of the Company as of September 30, 2019 and the results of its condensed consolidated operations for the nine months and three months ended September 30, 2019 and 2018. Condensed consolidated operating results for the interim periods presented are not necessarily indicative of the results to be expected for a full fiscal year. The consolidated balance sheet at December 31, 2018 has been derived from the Company’s audited consolidated financial statements at such date. The condensed consolidated financial statements and related notes have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Accordingly, certain information and note disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been omitted pursuant to such rules and regulations. These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and other information included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2018, as filed with the SEC. |
Business
Business | 9 Months Ended |
Sep. 30, 2019 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Business | 2. Business The mission of the Company is to develop innovative and revolutionary treatments to combat diseases caused by disruption of neuronal signaling. We are developing treatment options that address conditions that affect millions of people, but for which there are few or poor treatment options, including obstructive sleep apnea (“OSA”), attention deficit hyperactivity disorder (“ADHD”) and recovery from spinal cord injury (“SCI”), as well as certain neurological orphan diseases such as Fragile X Syndrome. RespireRx is developing a pipeline of new drug products based on our broad patent portfolios for two drug platforms: cannabinoids, including dronabinol (“∆9-THC”), and the ampakines, proprietary compounds that positively modulate AMPA-type glutamate receptors to promote neuronal function. RespireRx is developing a number of potential products. From the cannabinoid platform, two Phase 2 clinical trials have been completed demonstrating the ability of dronabinol to statistically significantly reduce the symptoms of OSA, which management believes is potentially a multi-billion-dollar market. Subject to raising sufficient financing (of which no assurance can be provided), we believe that we have put most of the necessary pieces into place to rapidly initiate a Phase 3 clinical trial program. By way of definition, when a new drug is allowed by the United States Food and Drug Administration (“FDA”) to be tested in humans, Phase 1 clinical trials are conducted in healthy people to determine safety and pharmacokinetics. If successful, Phase 2 clinical trials are conducted in patients to determine safety and preliminary efficacy. Phase 3 trials, large scale studies to determine efficacy and safety, are the final step prior to seeking FDA approval to market a drug. Through an extensive translational research effort from the cellular level through Phase 2 clinical trials, the Company has developed a family of novel, low impact ampakines, including CX717, CX1739 and CX1942 that may have clinical application in the treatment of CNS-driven neurobehavioral and cognitive disorders, spinal cord injury, neurological diseases, and certain orphan indications. From our ampakine platform, our lead clinical compounds, CX717 and CX1739, have successfully completed multiple Phase 1 safety trials. Both compounds have also completed Phase 2 efficacy trials demonstrating target engagement, by antagonizing the ability of opioids to induce respiratory depression. CX717 has successfully completed a Phase 2 trial demonstrating the ability to statistically significantly reduce the symptoms of adult ADHD. In an early Phase 2 study, CX1739 improved breathing in patients with central sleep apnea. Preclinical studies have highlighted the potential ability of these ampakines to improve motor function in animals with spinal injury. Subject to raising sufficient financing (of which no assurance can be provided), we believe that we will be able to rapidly initiate a human Phase 2 study with CX1739 and/or CX717 in patients with spinal cord injury and a human Phase 2B study in patients with ADHD with either CX717 or CX1739. Going Concern The Company’s condensed consolidated financial statements have been presented on the basis that it is a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company has incurred net losses of $1,487,389 and $469,844 for the nine months and three-months ended September 30, 2019, respectively and $2,591,790 for the fiscal year ended December 31, 2018, and negative operating cash flows of $313,692 for the nine months ended September 30, 2019 and $427,368 for the fiscal year ended December 31, 2018. The Company had only $94 of cash at September 30, 2019 and also had a stockholders’ deficiency of $7,039,381 at September 30, 2019 and expects to continue to incur net losses and negative operating cash flows for at least the next few years. As a result, management has concluded that there is substantial doubt about the Company’s ability to continue as a going concern, and the Company’s independent registered public accounting firm, in its report on the Company’s consolidated financial statements for the year ended December 31, 2018, expressed substantial doubt about the Company’s ability to continue as a going concern. The Company is currently, and has for some time, been in significant financial distress. It has extremely limited cash resources and current assets and has no ongoing source of sustainable revenue. Fund raising efforts have been hampered by the Company’s low market capitalization and its common stock’s limited public float and low trading volume. Management is continuing to address various aspects of the Company’s operations and obligations, including, without limitation, debt obligations, financing requirements, intellectual property, licensing agreements, legal and patent matters and regulatory compliance, and has taken steps to continue to raise new debt and equity capital to fund the Company’s business activities from both related and unrelated parties. The Company is continuing its efforts to raise additional capital in order to be able to pay its liabilities and fund its business activities on a going forward basis, including the pursuit of the Company’s planned research and development activities. The Company regularly evaluates various measures to satisfy the Company’s liquidity needs, including strategic transactions, development and other agreements with collaborative partners such as Noramco Inc., and, when necessary, seeking to exchange or restructure the Company’s outstanding securities. The Company also is evaluating certain changes to its operations and structure to facilitate raising capital from sources that may be interested in financing only discrete aspects of the Company’s development programs. Such changes could include a significant reorganization, which may include the formation of one or more subsidiaries into which one or more programs may be contributed. To date, we have organized our two major platforms, cannabinoids and ampakines, into two operating divisions with the potential for evolving into stand-alone subsidiary companies. Towards this end, we have begun discussions focused on each of these platforms with potential investors and strategic partners. We also have begun interviewing individuals to assume executive management of the dronabinol platform. As a result of the Company’s current financial situation, the Company has experienced very limited access to external sources of debt and equity financing and the cost of such capital, both in terms of rates and other conditions, has been high. Accordingly, there can be no assurances that the Company will be able to secure additional financing in the amounts necessary to fully fund its operating and debt service requirements. If the Company is unable to access sufficient cash resources, the Company may be forced to discontinue its operations entirely and liquidate. |
Summary of Significant Accounti
Summary of Significant Accounting Policies | 9 Months Ended |
Sep. 30, 2019 | |
Accounting Policies [Abstract] | |
Summary of Significant Accounting Policies | 3. Summary of Significant Accounting Policies Principles of Consolidation The accompanying condensed consolidated financial statements are prepared in accordance with United States generally accepted accounting principles (“GAAP”) and include the financial statements of RespireRx and its wholly-owned subsidiary, Pier. Intercompany balances and transactions have been eliminated in consolidation. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions. These estimates and assumptions affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include, among other things, accounting for potential liabilities, and the assumptions used in valuing stock-based compensation issued for services. Actual amounts may differ from those estimates. Concentration of Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company limits its exposure to credit risk by investing its cash with high credit quality financial institutions. The Company’s research and development efforts and potential products rely on licenses from research institutions and if the Company loses access to these technologies or applications, its business could be substantially impaired. Cash Equivalents The Company considers all highly liquid short-term investments with maturities of less than three-months when acquired to be cash equivalents. Fair Value of Financial Instruments The authoritative guidance with respect to fair value of financial instruments established a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three levels and requires that assets and liabilities carried at fair value be classified and disclosed in one of three categories, as presented below. Disclosure as to transfers into and out of Levels 1 and 2, and activity in Level 3 fair value measurements, is also required. Level 1. Observable inputs such as quoted prices in active markets for an identical asset or liability that the Company has the ability to access as of the measurement date. Financial assets and liabilities utilizing Level 1 inputs include active-exchange traded securities and exchange-based derivatives. Level 2. Inputs, other than quoted prices included within Level 1, which are directly observable for the asset or liability or indirectly observable through corroboration with observable market data. Financial assets and liabilities utilizing Level 2 inputs include fixed income securities, non-exchange based derivatives, mutual funds, and fair-value hedges. Level 3. Unobservable inputs in which there is little or no market data for the asset or liability which requires the reporting entity to develop its own assumptions. Financial assets and liabilities utilizing Level 3 inputs include infrequently-traded, non-exchange-based derivatives and commingled investment funds, and are measured using present value pricing models. The Company determines the level in the fair value hierarchy within which each fair value measurement falls in its entirety, based on the lowest level input that is significant to the fair value measurement in its entirety. In determining the appropriate levels, the Company performs an analysis of the assets and liabilities at each reporting period end. The carrying amounts of financial instruments (consisting of cash, cash equivalents, advances on research grants and accounts payable and accrued expenses) are considered by the Company to be representative of the respective fair values of these instruments due to the short-term nature of those instruments. With respect to the note payable to SY Corporation Co., Ltd., formerly known as Samyang Optics Co. Ltd. (“SY Corporation”) and the convertible notes payable, management does not believe that the credit markets have materially changed for these types of borrowings since the original borrowing date. The Company considers the carrying amounts of the notes payable to officers, inclusive of accrued interest, to be representative of the respective fair values of such instruments due to the short-term nature of those instruments and their terms. Convertible Notes Payable Convertible notes are evaluated to determine if they should be recorded at amortized cost. To the extent that there are associated warrants or a beneficial conversion feature, the convertible notes and warrants are evaluated to determine if there are embedded derivatives to be identified, bifurcated and valued at fair value in connection with and at the time of such financing. The value of debt discounts such as warrants, beneficial conversion features and original issue discounts are recorded as contra debt and amortized into interest expense over the life of the notes. Extinguishment of Debt The Company accounts for the extinguishment of debt in accordance with GAAP by comparing the carrying value of the debt to the fair value of consideration paid or assets given up and recognizing a loss or gain in the condensed consolidated statement of operations in the amount of the difference in the period in which such transaction occurs. Equipment Equipment is recorded at cost and depreciated on a straight-line basis over their estimated useful lives, which range from three to five years. All equipment was fully depreciated as of September 30, 2019. Prepaid Insurance Long-term prepaid insurance represents the premium paid in March 2014 for directors’ and officers’ insurance tail coverage, which is being amortized on a straight-line basis over the policy period of six years. The amount amortizable in the ensuing twelve- month period is recorded as a current asset in the Company’s condensed consolidated balance sheet at each reporting date. As of September 30, 2019, all such prepaid amounts have been reclassified as current since the policy will expire within one year. Impairment of Long-Lived Assets The Company reviews its long-lived assets, including long-term prepaid insurance, for impairment whenever events or changes in circumstances indicate that the total amount of an asset may not be recoverable, but at least annually. An impairment loss is recognized when estimated future cash flows expected to result from the use of the asset and its eventual disposition is less than the asset’s carrying amount. The Company has not deemed any long-lived assets as impaired at September 30, 2019. Stock-Based Awards The Company periodically issues common stock and stock options to officers, directors, outside consultants and vendors for services rendered. Such issuances vest and expire according to terms established at the issuance date of each grant. The Company accounts for stock-based payments to officers, directors, outside consultants and vendors by measuring the cost of services received in exchange for equity awards based on the grant date fair value of the awards, with the cost recognized as compensation expense on the straight-line basis in the Company’s consolidated financial statements over the vesting period of the awards. The fair value of stock options granted as stock-based payments is determined utilizing the Black-Scholes option-pricing model, and is affected by several variables, the most significant of which are the life of the equity award, the exercise price of the stock option as compared to the fair market value of the common stock on the grant date, and the estimated volatility of the common stock over the term of the equity award. Estimated volatility is based on the historical volatility of the Company’s common stock. The risk- free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant. The fair market value of common stock is determined by reference to the quoted market price of the Company’s common stock. There were no stock or stock option grants during the nine months ended September 30, 2019. For stock options requiring an assessment of value during the nine months ended September 30, 2018, the fair value of each stock option award was estimated using the Black-Scholes option-pricing model using the following assumptions: Risk-free interest rate 2.56 % Expected dividend yield 0 % Expected volatility 185.41 % Expected life 4.5 The Company recognizes the fair value of stock-based payments in general and administrative costs and in research and development costs, as appropriate, in the Company’s condensed consolidated statements of operations. The Company issues new shares of common stock to satisfy stock option and warrant exercises. There were no stock options exercised during the nine months ended September 30, 2019 and 2018. Income Taxes The Company accounts for income taxes under an asset and liability approach for financial accounting and reporting for income taxes. Accordingly, the Company recognizes deferred tax assets and liabilities for the expected impact of differences between the financial statements and the tax basis of assets and liabilities. The Company records a valuation allowance to reduce its deferred tax assets to the amount that is more likely than not to be realized. In the event the Company was to determine that it would be able to realize its deferred tax assets in the future in excess of its recorded amount, an adjustment to the deferred tax assets would be credited to operations in the period such determination was made. Likewise, should the Company determine that it would not be able to realize all or part of its deferred tax assets in the future, an adjustment to the deferred tax assets would be charged to operations in the period such determination was made. Pursuant to Internal Revenue Code Sections 382 and 383, use of the Company’s net operating loss and credit carryforwards may be limited if a cumulative change in ownership of more than 50% occurs within any three-year period since the last ownership change. The Company may have had a change in control under these Sections. However, the Company does not anticipate performing a complete analysis of the limitation on the annual use of the net operating loss and tax credit carryforwards until the time that it anticipates it will be able to utilize these tax attributes. As of September 30, 2019, the Company did not have any unrecognized tax benefits related to various federal and state income tax matters and does not anticipate any material amount of unrecognized tax benefits within the next 12 months. The Company is subject to U.S. federal income taxes and income taxes of various state tax jurisdictions. As the Company’s net operating losses have yet to be utilized, all previous tax years remain open to examination by Federal authorities and other jurisdictions in which the Company currently operates or has operated in the past. The Company accounts for uncertainties in income tax law under a comprehensive model for the financial statement recognition, measurement, presentation and disclosure of uncertain tax positions taken or expected to be taken in income tax returns as prescribed by GAAP. The tax effects of a position are recognized only if it is “more-likely-than-not” to be sustained by the taxing authority as of the reporting date. If the tax position is not considered “more-likely-than-not” to be sustained, then no benefits of the position are recognized. As of September 30, 2019, the Company had not recorded any liability for uncertain tax positions. In subsequent periods, any interest and penalties related to uncertain tax positions will be recognized as a component of income tax expense. Foreign Currency Transactions The note payable to SY Corporation, which is denominated in a foreign currency (the South Korean Won), is translated into the Company’s functional currency (the United States Dollar) at the exchange rate on the balance sheet date. The foreign currency exchange gain or loss resulting from translation is recognized in the related condensed consolidated statements of operations. Research and Development Research and development costs include compensation paid to management directing the Company’s research and development activities, and fees paid to consultants and outside service providers and organizations (including research institutes at universities), and other expenses relating to the acquisition, design, development and clinical testing of the Company’s treatments and product candidates. Research and development costs incurred by the Company under research grants are expensed as incurred over the life of the underlying contracts, unless the terms of the contract indicate that a different expensing schedule is more appropriate. The Company reviews the status of its research and development contracts on a quarterly basis. On May 6, 2016, the Company made an advance payment to Duke University with respect to the Phase 2A clinical trial of CX1739. At September 30, 2019, an asset balance of $48,912 remained from the advance payment. License Agreements Obligations incurred with respect to mandatory payments provided for in license agreements are recognized ratably over the appropriate period, as specified in the underlying license agreement, and are recorded as liabilities in the Company’s condensed consolidated balance sheet, with a corresponding charge to research and development costs in the Company’s condensed consolidated statement of operations. Obligations incurred with respect to milestone payments provided for in license agreements are recognized when it is probable that such milestone will be reached and are recorded as liabilities in the Company’s condensed consolidated balance sheet, with a corresponding charge to research and development costs in the Company’s condensed consolidated statement of operations. Payments of such liabilities are made in the ordinary course of business. Patent Costs Due to the significant uncertainty associated with the successful development of one or more commercially viable products based on the Company’s research efforts and any related patent applications, all patent costs, including patent-related legal and filing fees, are expensed as incurred and recorded as general and administrative expenses. Earnings per Share The Company’s computation of earnings per share (“EPS”) includes basic and diluted EPS. Basic EPS is measured as the income (loss) attributable to common stockholders divided by the weighted average common shares outstanding for the period. Diluted EPS is similar to basic EPS but presents the dilutive effect on a per share basis of potential common shares (e.g., warrants and options) as if they had been converted at the beginning of the periods presented, or issuance date, if later. Potential common shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share) are excluded from the calculation of diluted EPS. Loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the respective periods. Basic and diluted loss per common share is the same for all periods presented because all warrants and stock options outstanding are anti-dilutive. At September 30, 2019 and 2018, the Company excluded the outstanding securities summarized below, which entitle the holders thereof to acquire shares of common stock, from its calculation of earnings per share, as their effect would have been anti-dilutive. September 30, 2019 2018 Series B convertible preferred stock 11 11 Convertible notes payable 867,200 16,061 Common stock warrants 2,016,043 1,703,229 Common stock options 4,287,609 4,323,317 Total 7,170,863 5,507,312 Reclassifications Certain comparative figures in 2018 have been reclassified to conform to the current nine month and three month presentation. These reclassifications were immaterial, both individually and in the aggregate. Recent Accounting Pronouncements From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that are adopted by the Company as of the specified effective date. Unless otherwise discussed, we believe that the impact of recently issued standards that are not yet effective will not have a material impact on our financial position or results of operations upon adoption. |
Notes Payable
Notes Payable | 9 Months Ended |
Sep. 30, 2019 | |
Debt Disclosure [Abstract] | |
Notes Payable | 4. Notes Payable Convertible Notes Payable On August 19, 2019, the Company issued a convertible note (the “August 2019 Convertible Note”) bearing interest at 10% per year. The maturity amount is $55,000 and it matures on the nine month anniversary, which is May 19, 2020. The Company incurred debt issuance costs of $2,500 for lender legal fees. The transaction included a $5,000 original issue discount, a warrant to purchase 150,000 shares of common stock and 7,500 Commitment Shares (as such term is defined in the definitive transaction documents), which were issued in connection with the August 2019 Convertible Note. The net proceeds to the Company was $47,500. Subject to certain limitations and adjustments as described in the August 2019 Convertible Note, the holder may convert the August 2019 Convertible Note at a fixed conversion price of $0.50 per share of common stock, provided that from the date that is six months after the issuance date, the conversion price shall be the lower of (a) $0.50 or (b) 60% multiplied by the lowest closing price of the common stock during the twenty (20) consecutive trading days prior to conversion. The Company evaluated all of the terms of the August 2019 Convertible Note and determined that, in accordance with ASC 815, there were no derivatives to be bifurcated or separately valued. However, there were five features of the August 2019 Convertible Note and the related securities purchase agreement that required valuation. They were: (i) the debt issuance costs of $2,500, (ii) the intrinsic value of the beneficial conversion feature, (iii) the value of the warrant, (iv) the original issue discount of $5,000, and (v) the value of the Commitment Shares. The Company amortizes each of these five on a straight-line basis over the life of the August 2019 Convertible Note. The Company valued the warrant using the Black-Scholes valuation method utilizing the following assumptions: (i) exercise price of $0.50, (ii) stock price of $0.65, (iii) life of five years, (iv) five-year risk free rate of 1.47% and (v) volatility of 175.5% that results in the value of one warrant of $0.623 and a total warrant value of $93,450. The amount to be recorded initially as the amount of the August 2019 Convertible Note was then calculated by determining the relative values as percentages of the net proceeds of the August 2019 Convertible Note ($47,500), the beneficial conversion feature ($16,500) and the warrant ($64.08% or $30,440) and the Commitment Shares (3.34% or $1,588). The debt issuance costs, original issue discount and the amount recorded as the intrinsic value of the beneficial conversion feature each are being amortized to interest expense on a straight-line basis over the life the August 2019 Convertible Note. The table below provides a summary of the August 2019 Convertible Note as of September 30, 2019. Principal amount of note payable $ 55,000 Debt discounts, net of amortization of $8,504 (46,496 ) Accrued coupon interest 648 $ 9,152 On May 17, 2019, the Company issued a master convertible note (the “May 2019 Convertible Note”) issuable in tranches, bearing interest at 10% per year, bearing a maximum maturity amount of $150,000. The first tranche has a maturity amount of $50,000 and matures on the one year anniversary of the tranche which is May 17, 2020. There was a stated original issue discount of $5,000 and the Company incurred debt issuance costs of $2,000 for lender legal fees. Therefore, the net proceeds to the Company was $43,000. Subject to certain limitations and adjustments as described in the May 2019 Convertible Note, the holder may convert from the date of issuance to the maturity date, part or all of the May 2019 Convertible Note, inclusive of accrued interest, into the Company’s common stock at a variable conversion price that is the lesser of (i) lowest trading price as such term is defined in the May 2019 Convertible Note (the lowest closing bid price) in the twenty five day trading period prior to the date of the May 2019 Convertible Note (which price is now fixed at $0.25, the closing bid price on May 16, 2019), or (ii) the variable conversion price (as defined in the May 2019 Convertible Note) which is 61% of the market price (as defined in the May 2019 Convertible Note). The market price is the lowest trading price (closing bid) in the twenty five day trading day period up to the day prior to the conversion. If at any time while the Note is outstanding, the conversion price is equal to or lower than $0.35, then an additional eleven percent (11%) discount is to be factored into the conversion price until the May 2019 Convertible Note is no longer outstanding (resulting in a discount rate of 50% assuming no other adjustments are triggered). The lowest trading price on the date of inception of the May 2019 Convertible Note ($0.25) and the lowest market price were both below $0.35, the effective conversion rate on the inception date was $0.125. Therefore, on the inception date, the first tranche would have converted into 400,000 shares of the Company’s common stock. As of September 30, 2019, the first tranche would convert into 296,438 shares of common stock based upon a conversion price of $0.175 (50% of the lowest closing bid price during the applicable period). The Company evaluated all of the terms of the May 2019 Convertible Note and determined that, in accordance with Accounting Standard Codification (ASC) 815, there were no derivatives to be bifurcated or separately valued. However, there were four features of the May 2019 Convertible Note, the related securities purchase agreement and the warrant that was issued in connection therewith that required valuation. They were: (i) the original issue discount of $5,000, (ii) the debt issuance costs of $2,000, (iii) the beneficial conversion feature and (iv) the value of the warrant. The Company amortized (i) and (ii) above on a straight-line basis over the life of the tranche. The Company evaluated (iii) the intrinsic value of the beneficial conversion feature for a calculated value of $286,000 (($0.84 closing price minus $0.125 conversion price) x 400,000 shares). The Company calculated the warrant value using the Black-Scholes valuation method, utilizing the following assumptions: (a) exercise price of $1.18 per share, (b) stock price $0.84, (c) three year life (d) three year risk free rate of 2.15% and (e) volatility of 210.19% and determined that the value of one warrant was $0.774 and the total warrant value was $32,796 for the warrant exercisable into 42,373 shares of the Company’s common stock, par value $0.001. The amount to be recorded initially as the amount of the May 2019 Convertible Note was then calculated by determining the relative values as percentages of the maturity amount of the May 2019 Convertible Note ($50,000), the beneficial conversion feature ($286,000) and the warrant ($32,796). The respective percentages were 13.56%, 77.55 and 8.89%. The original issue discount, debt issuance costs, the intrinsic value of the beneficial conversion feature and proceeds allocated to the value of the warrant are being amortized to interest expense on a straight-line basis over the life the May 2019 Convertible Note. The table below provides a summary of the May 2019 Convertible Note as of September 30, 2019. Principal amount of note payable $ 50,000 Debt discounts, net of amortization of $19,072 (31,149 ) Accrued coupon interest 1,876 $ 20,727 On April 24, 2019, the Company issued a convertible note (“the April 2019 Convertible Note”) bearing interest at 10% per year. The maturity amount is $58,500 and matures on the one year anniversary which is April 24, 2020. The Company incurred debt issuance costs of $3,500 for lender legal and due diligence fees. There was no stated original issue discount and no warrants were issued in connection with the April 2019 Convertible Note. The net proceeds to the Company was $50,000. Subject to certain limitations and adjustments as described in the April 2019 Convertible Note, the holder may, from the date that is one hundred eighty (180) days after the issuance to the maturity date, convert part or all of the April 2019 Convertible Note, inclusive of accrued interest, into the Company’s common stock at a variable conversion price that is 61% of the market price as defined in the April 2019 Convertible Note. The market price is the lowest trading price, which in turn is the lowest closing bid price in the twenty (20) trading days prior to conversion. The lowest closing bid price in the twenty (20) day period prior to inception was $0.65 which would calculate to a $0.3964 conversion price and further calculate to 147,541 conversion shares to be issued. The Company evaluated all of the terms of the April 2019 Convertible Note and determined that, in accordance with ASC 815, there were no derivatives to be bifurcated or separately valued. However, there were two features of the April 2019 Convertible Note and the related securities purchase agreement that required valuation. They were: (i) the debt issuance costs of $3,500, and (ii) the intrinsic value of the beneficial conversion feature. The Company amortized (i) on a straight-line basis over the life of the April 2019 Convertible Note. The Company evaluated (ii) as the closing price on the inception date minus the conversion price multiplied by the number of conversion shares and determined that the beneficial conversion feature had an intrinsic value of $44,950 (($0.701 closing price minus $0.3964 conversion price) x 147,541 shares). The debt issuance costs and the amount recorded as the intrinsic value of the beneficial conversion feature are each being amortized to interest expense on a straight-line basis over the life the April 2019 Convertible Note. The table below provides a summary of the April 2019 Convertible Note as of September 30, 2019. Principal amount of note payable $ 58,500 Debt discounts, net of amortization of $21,238 (27,211 ) Accrued coupon interest 2,859 $ 34,148 On January 2, 2019, February 27, 2019, March 6, 2019 and March 14, 2019, the Company issued convertible notes (collectively, the “2019 Q1 Convertible Notes”) bearing interest at 10% per year. The 2019 Q1 Convertible Notes issued on January 2, 2019 matured on February 28, 2019 with a face amount of $10,000. The 2019 Q1 Convertible Notes issued on February 27, 2019, March 6, 2019 and March 14, 2019 matured on April 30, 2019 with an aggregate face amount of $100,000. Investors also received an aggregate of 110,000 common stock purchase warrants. The warrants were valued using the Black Scholes option pricing model calculated on the date of each grant and had an aggregate value of $78,780. Total value received by the investors was $188,780, the sum of the face value of the convertible note and the value of the warrant. Therefore, the Company recorded a debt discount associated with the warrant issuance of $45,812 and an initial value of the convertible notes of $64,188 using the relative fair value method. An additional $6,653 and $2,811 of interest expense was recorded based upon the 10% annual rate for the nine months and three months ended September 30, 2019, respectively. The 2019 Q1 Convertible Note that matured on February 28, 2019 was not paid and remains outstanding and continues to accrue interest. The 2019 Q1 Convertible Notes that matured on April 30, 2019 were not paid and remain outstanding and continue to accrue interest. Although the 2019 Q1 Convertible Notes are in default, the Company has not received any notices of default from any of the note holders. The 2019 Q1 Convertible Notes have no reset rights or other protections based on subsequent equity transactions, equity-linked transactions or other events other than the right, but not the obligation, for each investor to convert or exchange his or her 2019 Q1 Convertible Note, but not the warrant, into the next exempt private securities offering. The May 2019 Convertible Note and April 2019 Convertible Note, which the Company does not consider to have arisen from an offering, may be interpreted in such a way that the 2019 Q1 Convertible Note Holders have the right to convert or exchange. However, no holders of such notes have requested a conversion or exchange. The Company does not believe that an offering occurred as of September 30, 2019 or as of the date of the issuance of these financial statements. Therefore, the number of shares of common stock (or preferred stock) into which the 2019 Q1 Convertible Notes may convert is not determinable and the Company has not accounted for any additional consideration. The warrants to purchase 110,000 shares of common stock issued in connection with the sale of the 2019 Q1 Convertible Notes are exercisable at a fixed price of $1.50 per share of common stock, provide no right to receive a cash payment, and included no reset rights or other protections based on subsequent equity transactions, equity-linked transactions or other events. The Company determined that there were no embedded derivatives to be identified, bifurcated and valued in connection with this financing. During December 2018, convertible notes (“2018 Convertible Notes”) bearing interest at 10% per year and maturing on February 28, 2019 and warrants were sold to investors with an aggregate face amount of $80,000. Investors also received 80,000 common stock purchase warrants. The warrants were valued using the Black Scholes option pricing model calculated on the date of each grant and had an aggregate value of $68,025. Total value received by the investors was $148,025, the sum of the face value of the convertible note and the value of the warrant. Therefore, the Company recorded a debt discount associated with the issuance of the warrants of $36,347 and an initial value of the convertible notes of $43,653 using the relative fair value method. An additional $6,067 and $2,044 of interest expense was recorded based upon the 10% annual rate for the nine months and three months ended September 30, 2019, respectively. The 2018 Convertible Notes matured on February 28, 2019, were not paid, remain outstanding and continue to accrue interest. Although the 2018 Convertible Notes are in default, the Company has not received any notices of default from any of the note holders. The 2018 Convertible Notes have no reset rights or other protections based on subsequent equity transactions, equity-linked transactions or other events other than the right, but not the obligation for each investor to convert or exchange his or her 2018 Convertible Note, but not the warrant, into the next exempt private securities offering. The May 2019 Convertible Note and April 2019 Convertible Note, which the Company does not consider to have arisen from an offering, may be interpreted in such a way that the 2019 Q1 Convertible Note Holders have the right to convert or exchange. However, no holders of such notes have requested a conversion or exchange. The Company does not believe that an offering occurred as of September 30, 2019 or as of the date of the issuance of these financial statements. Therefore, the number of shares of common stock (or preferred stock) into which the 2018 Convertible Notes may convert is not determinable and the Company has not accounted for any additional consideration. The warrants to purchase 80,000 shares of common stock issued in connection with the sale of the 2018 Convertible Notes are exercisable at a fixed price of $1.50 per share of common stock, provide no right to receive a cash payment, and included no reset rights or other protections based on subsequent equity transactions, equity-linked transactions or other events. The Company determined that there were no embedded derivatives to be identified, bifurcated and valued in connection with this financing. The 2018 Convertible Notes and 2019 Q1 Convertible Notes consist of the following at September 30, 2019 and December 31, 2018: September 30, December 31, Principal amount of notes payable $ 190,000 $ 80,000 Discount associated with issuance of warrants net of amortization of $82,159 as of September 30, 2019 and $8,379 as of December 31,2018 - (27,968 ) Accrued interest payable 13,121 401 $ 203,121 $ 52,433 Convertible notes were also sold to investors in 2014 and 2015 (“Original Convertible Notes), which aggregated a total of $579,500, had a fixed interest rate of 10% per annum and those that remain outstanding are convertible into common stock at a fixed price of $11.3750 per share. The Original Convertible Notes have no reset rights or other protections based on subsequent equity transactions, equity-linked transactions or other events. The warrants to purchase 50,945 shares of common stock issued in connection with the sale of the convertible notes were exercisable at a fixed price of $11.3750 per share. All such warrants have either been exchanged as part of April and May 2016 note and warrant exchange agreements or expired on September 15, 2016. The maturity date of the Original Convertible Notes was extended to September 15, 2016 and included the issuance of 27,936 additional warrants to purchase common stock, exercisable at $11.375 per share of common stock, which expired on September 15, 2016. The remaining outstanding Original Convertible Notes (including those for which default notices have been received) consist of the following at September 30, 2019 and December 31, 2018: September 30, December 31, Principal amount of notes payable $ 125,000 $ 125,000 Accrued interest payable 76,920 62,233 $ 201,920 $ 187,233 As of September 30, 2019, principal and accrued interest on the one remaining outstanding Original Convertible Note, which is subject to a default notice and which therefore accrues annual interest at 12% instead of 10%, totaled $42,406, of which $17,406 was accrued interest. As of December 31, 2018, principal and accrued interest on convertible notes subject to default notices totaled $38,292 of which $13,292 was accrued interest. As of September 30, 2019 all of the outstanding Original Convertible Notes, inclusive of accrued interest, were convertible into an aggregate of 17,810 shares of the Company’s common stock, including 6,765 shares attributable to accrued interest of $76,920 payable as of such date. As of December 31, 2018, the outstanding Original Convertible Notes were convertible into 16,460 shares of the Company’s common stock, including 5,471 shares attributable to accrued interest of $62,233 payable as of such date. Such Original Convertible Notes will continue to accrue interest until exchanged, paid or otherwise discharged. There can be no assurance that any of the additional holders of the remaining Original Convertible Notes will exchange their notes. Note Payable to SY Corporation Co., Ltd. On June 25, 2012, the Company borrowed 465,000,000 Won (the currency of South Korea, equivalent to approximately $400,000 United States Dollars as of that date) from and executed a secured note payable to SY Corporation, an approximately 20% common stockholder of the Company at that time. SY Corporation was a significant stockholder and a related party at the time of the transaction but has not been a significant stockholder or related party of the Company subsequent to December 31, 2014. The note accrues simple interest at the rate of 12% per annum and had a maturity date of June 25, 2013. The Company has not made any payments on the promissory note. At June 30, 2013 and subsequently, the promissory note was outstanding and in default, although SY Corporation has not issued a notice of default or a demand for repayment. Management believes that SY Corporation is in default of its obligations under its January 2012 license agreement, as amended, with the Company, but the Company has not yet issued a notice of default. The Company has in the past made several efforts towards a comprehensive resolution of the aforementioned matters involving SY Corporation. During the nine months ended September 30, 2019, there were no communications between the Company and SY Corporation. The promissory note is secured by collateral that represents a lien on certain patents owned by the Company, including composition of matter patents for certain of the Company’s high impact ampakine compounds and the low impact ampakine compounds CX2007 and CX2076, and other related compounds. The security interest does not extend to the Company’s patents for its ampakine compounds CX1739 and CX1942, or to the patent for the use of ampakine compounds for the treatment of respiratory depression. Note payable to SY Corporation consists of the following at September 30, 2019 and December 31, 2018: September 30, December 31, Principal amount of note payable $ 399,774 $ 399,774 Accrued interest payable 351,188 315,307 Foreign currency transaction adjustment (27,775 ) 29,360 $ 723,187 $ 744,441 Interest expense with respect to this promissory note was $35,881 and $12,092 for the nine months and three months ended September 30, 2019, and for the nine months and three months ended September 30, 2018, respectively. Notes Payable to Officers and Former Officers For the nine months and three months ended September 30, 2019, $7,683 and $2,589 respectively was charged to interest expense with respect to notes payable to Dr. Arnold S. Lippa, an officer of the Company. For the nine months and three months ended September 30, 2018, $9,517 and $3,319 respectively was charged to interest expense with respect to notes payable to Dr. Arnold S. Lippa. For the nine months and three months ended September 30, 2019, $11,530 and $3,886 respectively was charged to interest expense with respect notes payable to to Dr.James S. Manuso, a former officer of the Company. For the nine months and three months ended September 30, 2018 $9,754 and $3,564 respectivley was charged to interest expense with respect to notes payable to Dr. James S. Manuso. As of September 30, 2018, Dr. James S. Manuso resigned as executive officer in all capacities and as a member of the Board of Directors of the Company. All of the $11,530 of interest expense noted above for the nine months ended September 30, 2019, was incurred while Dr. Manuso was no longer an officer. Other Short-Term Notes Payable Other short-term notes payable at September 30, 2019 and December 31, 2018 consisted of premium financing agreements with respect to various insurance policies. At the inception of the new policy in March 2019, a premium financing agreement was payable in the initial amount of $61,746, with interest at 9% per annum, in nine monthly installments of $7,120. At September 30, 2019 and December 31, 2018, the aggregate amount of the short-term notes payable was $27,997 and $8,907 respectively. |
Settlement and Payment Agreemen
Settlement and Payment Agreements | 9 Months Ended |
Sep. 30, 2019 | |
Settlement And Payment Agreements | |
Settlement and Payment Agreements | 5. Settlement and Payment Agreements On August 21, 2019, the Company entered into a Settlement Agreement and Release with Salamandra, LLC (“Salamandra”) in respect to amounts owed to Salamandra, which totaled $202,395 as of September 30, 2019. The settlement agreement reduces the amount owed to a lump-sum payment of $125,000 payable by November 30, 2019, if by that date, the Company has raised an aggregate of at least $600,000 in working capital. Should the Company raise less than $600,000, the Company may pay 21% of the amount raised and cancel that portion of the debt. If the Company is unable to raise $600,000 by November 30, 2019, the settlement agreement becomes null and void. Upon receipt of the settlement payment, mutual releases will become effective with respect to the remaining amount of debt on that date. On October 22, 2019 and November 4, 2019, the Company raised an aggregate of $202,400 in working capital from the net proceeds of the October 2019 Convertible Note and the November 2019 Convertible Note (see Note 9. Subsequent Events). Total working capital raised by the Company from the inception of the Settlement Agreement through November 4, 2019 was $202,400. On September 23, 2019, the Company and a vendor agreed in principle to a proposed settlement agreement, which has not been documented in the form of a formal agreement. The agreement in principal calls for no reduction in the overall amount to be paid by the Company, which amount is not in dispute, but addresses only a payment schedule. The agreement in principal calls for a payment of a minimum of $100,000 on or before November 30, 2019 assuming the Company has raised at least $600,000 by that date and thereafter calls for a payment of $50,000 per month until paid in full. If the Company does not make a scheduled payment, the agreement in principal would be deemed null and void. |
Stockholders' Deficiency
Stockholders' Deficiency | 9 Months Ended |
Sep. 30, 2019 | |
Equity [Abstract] | |
Stockholders' Deficiency | 6. Stockholders’ Deficiency Preferred Stock The Company has authorized a total of 5,000,000 shares of preferred stock, par value $0.001 per share. As of September 30, 2019 and December 31, 2018, 1,250,000 shares were designated as 9% Cumulative Convertible Preferred Stock (non-voting, “9% Preferred Stock”); 37,500 shares were designated as Series B Convertible Preferred Stock (non-voting, “Series B Preferred Stock”); 205,000 shares were designated as Series A Junior Participating Preferred Stock (non-voting, “Series A Junior Participating Preferred Stock”); and 1,700 shares were designated as Series G 1.5% Convertible Preferred Stock. Accordingly, as of September 30, 2019 and December 31, 2018, 3,505,800 shares of preferred stock were undesignated and may be issued with such rights and powers as the Board of Directors may designate. Series B Preferred Stock outstanding as of September 30, 2019 and 2018 consisted of 37,500 shares issued in a May 1991 private placement. Each share of Series B Preferred Stock is convertible into approximately 0.00030 shares of common stock at an effective conversion price of $2,208.375 per share of common stock, which is subject to adjustment under certain circumstances. As of September 30, 2019 and December 31, 2018, the shares of Series B Preferred Stock outstanding are convertible into 11 shares of common stock. The Company may redeem the Series B Preferred Stock for $25,001, equivalent to $0.6667 per share, an amount equal to its liquidation preference, at any time upon 30 days prior notice. Common Stock There are 3,879,576 shares of the Company’s common stock outstanding as of September 30, 2019. The Company has reserved an aggregate of 7,401,292 for conversions of convertible debt which reserve includes contractual reserves totaling 7,383,482 shares of the Company’s common stock, which exceeds the actual conversion amounts under those contracts as of September 30, 2019 by 6,534,657 shares. In addition, The Company has reserved 6,303,652 shares of the Company’s common stock for exercises of common stock purchase options granted and warrants issued. There are 6,497 shares of the Company’s common stock reserved as Pier contingent shares. There are 4,490,578 shares reserved for future issuances under the Company’s 2014 and 2015 Plans (as hereafter defined). There are 43,452,954 shares of the Company’s common stock available for future issuances. Common Stock Warrants Information with respect to the issuance and exercise of common stock purchase warrants in connection with the Convertible Note Payable and the related warrant, and Notes Payable to Officers, is provided at Note 4. A summary of warrant activity for the nine months ended September 30, 2019 is presented below. Weighted Average Weighted Remaining Number of Average Contractual Shares Exercise Price Life (in Years) Warrants outstanding and exerciable at December 31, 2018 1,783,229 $ 2.20393 3.06 Issued 302,372 0.95908 Expired (69,558 ) 2.65928 Warrants outstanding and exercisable at September 30, 2019 2,016,043 $ 1.99011 2.73 The exercise prices of common stock warrants outstanding and exercisable are as follows at September 30, 2019: Exercise Price Warrants (Shares) Warrants (Shares) Expiration Date $ 0.5000 150,000 150,000 August 19, 2024 $ 1.0000 916,217 916,217 September 20, 2022 $ 1.1800 42,372 42,372 May 17, 2022 $ 1.5000 190,000 190,000 December 30, 2023 $ 1.5620 130,284 130,284 December 31, 2021 $ 1.5750 238,814 238,814 April 30, 2023 $ 2.7500 8,000 8,000 September 20, 2022 $ 4.8750 108,594 108,594 September 30, 2020 $ 6.8348 145,758 145,758 September 30, 2020 $ 7.9300 86,004 86,004 February 28, 2021 2,016,043 2,016,043 Based on a fair market value of $0.45 per share on September 30, 2019, the intrinsic value of exercisable in-the-money common stock warrants as of September 30, 2019 was $7,500. A summary of warrant activity for the nine months ended September 30, 2018 is presented below. Number of Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Life (in Years) Warrants outstanding and exercisable at December 31, 2017 1,464,415 $ 2.68146 3.73 Issued 238,814 1.57500 Warrants outstanding and exercisable at September 30, 2018 1,703,229 $ 2.52632 4.08 The exercise prices of common stock warrants outstanding and exercisable are as follows at September 30, 2018: Exercise Price Warrants Outstanding Warrants Exercisable Expiration Date $ 1.0000 916,217 916,217 September 20, 2022 $ 1.2870 41,002 41,002 April 17, 2019 $ 1.5620 130,284 130,284 December 31, 2021 $ 1,5750 238,814 238,814 April 30, 2023 $ 2.7500 8,000 8000 September 20, 2022 $ 4.8500 5,155 5,155 September 23, 2019 $ 4.8750 108,594 108,594 September 30, 2020 $ 5.0000 5,000 5,000 September 22, 2019 $ 5.1025 10,309 10,309 January 29, 2019 $ 6.5000 8,092 8,092 February 4, 2019 $ 6.8348 145,758 145,758 September 30, 2020 $ 7.9300 86,004 86,004 February 28, 2021 1,703,229 1,703,229 Based on a fair market value of $0.7171 per share on September 30, 2018, there were no exercisable in-the money common stock warrants as of September 30, 2018. Stock Options On March 18, 2014, the stockholders of the Company holding a majority of the votes to be cast on the issue approved the adoption of the Company’s 2014 Equity, Equity-Linked and Equity Derivative Incentive Plan (the “2014 Plan”), which had been previously adopted by the Board of Directors of the Company, subject to stockholder approval. The Plan permits the grant of options and restricted stock with respect to up to 325,025 shares of common stock, in addition to stock appreciation rights and phantom stock, to directors, officers, employees, consultants and other service providers of the Company. On June 30, 2015, the Board of Directors adopted the 2015 Stock and Stock Option Plan (the “2015 Plan”). The 2015 Plan initially provided for, among other things, the issuance of either or any combination of restricted shares of common stock and non- qualified stock options to purchase up to 461,538 shares of the Company’s common stock for periods up to ten years to management, members of the Board of Directors, consultants and advisors. The Company has not and does not intend to present the 2015 Plan to stockholders for approval. On August 18, 2015, the Board of Directors increased the number of shares that may be issued under the 2015 Plan to 769,231 shares of the Company’s common stock. On March 31, 2016, the Board of Directors further increased the number of shares that may be issued under the 2015 Plan to 1,538,461 shares of the Company’s common stock. On January 17, 2017, the Board of Directors further increased the number of shares that may be issued under the 2015 Plan to 3,038,461 shares of the Company’s common stock. On December 9, 2017, the Board of Directors further increased the number of shares that may be issued under the 2015 Plan to 6,985,260 shares of the Company’s common stock. On December 28, 2018, the Board of Directors further increased the number of shares that may be issued under the 2015 Plan to 8,985,260 shares of the Company’s common stock. Information with respect to the Black-Scholes variables used in connection with the evaluation of the fair value of stock- based compensation is provided at Note 3. There were no grants of common stock options or of stock for the nine month period ended September 30, 2019. A summary of stock option activity for the nine months ended September 30, 2019 is presented below. Number of Weighted Weighted Options outstanding and exercisable at December 31, 2018 4,344,994 $ 3.7634 7.38 Expired (57,385 ) (15.6139 ) Options outstanding and exercisable at September 30, 2019 4,287,609 $ 3.3798 5.23 The exercise prices of common stock options outstanding and exercisable were as follows at September 30, 2019: Exercise Price Options Outstanding Options Exercisable Expiration Date $ 0.7000 21,677 21,677 November 21, 2023 $ 1.1200 310,388 310,388 April 5, 2023 $ 1.2500 16,762 16,762 December 7, 2022 $ 1.3500 34,000 34,000 July 28, 2022 $ 1.4500 1,849,418 1,849,418 December 9, 2027 $ 1.4500 100,000 100,000 December 9, 2027 $ 2.0000 285,000 285,000 June 30, 2022 $ 2.0000 25,000 25,000 July 26, 2022 $ 3.9000 395,000 395,000 January 17, 2022 $ 4.5000 7,222 7,222 September 2, 2021 $ 5.6875 89,686 89,686 June 30, 2020 $ 5.7500 2,608 2,608 September 12, 2021 $ 6.4025 27,692 27,692 August 18, 2020 $ 6.4025 129,231 129,231 August 18, 2022 $ 6.4025 261,789 261,789 August 18, 2025 $ 6.8250 8,791 8,791 December 11, 2020 $ 7.3775 523,077 523,077 March 31, 2021 $ 8.1250 169,231 169,231 June 30, 2022 $ 13.9750 3,385 3,385 March 14, 2024 $ 15.4700 7,755 7,755 April 8, 2020 $ 15.9250 2,462 2,462 February 28, 2024 $ 16.6400 1,538 1,538 January 29, 2020 $ 19.5000 9,487 9,487 July 17, 2022 $ 19.5000 6,410 6,410 August 10, 2022 4,287,609 4,287,609 There was no deferred compensation expense for the outstanding stock options at September 30, 2019. Based on a fair market value of $0.45 per share on September 30, 2019, there was no intrinsic value of exercisable in-the-money common stock options as of September 30, 2019. A summary of stock option activity for the nine months ended September 30, 2018 is presented below. Number of Weighted Weighted Options outstanding and exercisable at December 31, 2017 3,996,167 $ 3.7634 6.30 Granted 327,150 1.1267 4.50 Options outstanding and exercisable at September 30, 2018 4,323,317 $ 3.5855 6.17 The exercise prices of common stock options outstanding and exercisable were as follows at September 30, 2018: Exercise Price Options Outstanding Options Exercisable Expiration Date $ 1.1200 310,388 310,388 April 5, 2023 $ 1.2500 16,762 16,762 December 7, 2022 $ 1.3500 34,000 34,000 July 28, 2022 $ 1.4500 1,849,418 1,849,418 December 9, 2027 $ 1.4500 100,000 100,000 December 9, 2027 $ 2.0000 285,000 285,000 June 30, 2022 $ 2.0000 25,000 25,000 July 26, 2022 $ 3.9000 395,000 395,000 January 17, 2022 $ 4.5000 7,222 7,222 September 2, 2021 $ 5.6875 89,686 89,686 June 30, 2020 $ 5.7500 2,608 2,608 September 12, 2021 $ 6.4025 27,692 27,692 August 18, 2020 $ 6.4025 129,231 129,231 August 18, 2022 $ 6.4025 261,789 261,789 August 18, 2025 $ 6.8250 8,791 8,791 December 11, 2020 $ 7.3775 523,077 523,077 March 31, 2021 $ 8.1250 169,231 169,231 June 30, 2022 $ 13.0000 7,385 7,385 March 13, 2019 $ 13.0000 3,846 3,846 April 14, 2019 $ 13.9750 3,385 3,385 March 14, 2024 $ 15.4700 7,755 7,755 April 8, 2020 $ 15.9250 2,462 2,462 February 28, 2024 $ 16.0500 46,154 46,154 July 17, 2019 $ 16.6400 1,538 1,538 January 29, 2020 $ 19.5000 9,487 9,487 July 17, 2022 $ 19.5000 6,410 6,410 August 10, 2022 4,323,317 4,323,317 Based on a fair market value of $0.7101 per share on September 30, 2018, there were no exercisable in-the-money common stock options as of September 30, 2018. Reserved and Unreserved Shares of Common Stock On January 17, 2017, the Board of Directors of the Company approved the adoption of an amendment of the Amended and Restated RespireRx Pharmaceuticals, Inc. 2015 Stock and Stock Option Plan (as amended, the “2015 Plan”). That amendment increases the shares issuable under the plan by 1,500,000, from 1,538,461 to 3,038,461. On December 9, 2017, the Board of Directors further amended the 2015 Plan to increase the number of shares that may be issued under the 2015 Plan to 6,985,260 shares of the Company’s common stock. On December 28, 2018, the Board of Directors further amended the 2015 Plan to increase the number of shares that may be issued under the 2015 Plan to 8,985,260 shares of the Company’s common stock. Other than the change in the number of shares available under the 2015 Plan, no other changes were made to the 2015 Plan by these amendments noted above. At September 30, 2019, the Company had 65,000,000 shares of common stock authorized and 3,879,576 shares of common stock issued and outstanding. The Company has reserved 11 shares of common stock for the conversion of the Series B Preferred Stock. The Company has reserved an aggregate of 7,401,292 for conversions of convertible debt which reserve includes contractual reserves totaling 7,383,482 shares of the Company’s common stock, which exceeds the actual conversion amounts under those contracts as of September 30, 2019 by 6,516,847 shares. In addition, The Company has reserved 6,303,652 shares of the Company’s common stock for exercises of common stock purchase options granted and warrants issued. There are 6,497 shares of the Company’s common stock reserved as Pier contingent shares. There are 4,490,578 shares reserved for future issuances under the Company’s 2014 and 2015 Plans (as hereafter defined). Accordingly, after taking into consideration the reserved shares, there are 42,918,394 shares of the Company’s common stock available for future issuances. The Company expects to satisfy its future common stock commitments through the issuance of authorized but unissued shares of common stock. |
Related Party Transactions
Related Party Transactions | 9 Months Ended |
Sep. 30, 2019 | |
Related Party Transactions [Abstract] | |
Related Party Transactions | 7. Related Party Transactions Dr. Arnold S. Lippa and Jeff E. Margolis, officers and directors of the Company since March 22, 2013, have indirect ownership interests and managing memberships in Aurora Capital LLC (“Aurora”) through interests held in its members, and Jeff. E. Margolis is also an officer of Aurora. Aurora is a boutique investment banking firm specializing in the life sciences sector that is also a full-service brokerage firm. A description of advances and notes payable to officers is provided at Note 4. |
Commitments and Contingencies
Commitments and Contingencies | 9 Months Ended |
Sep. 30, 2019 | |
Commitments and Contingencies Disclosure [Abstract] | |
Commitments and Contingencies | 8. Commitments and Contingencies Pending or Threatened Legal Action and Claims By letter dated May 18, 2018, the Company received notice from counsel claiming to represent TEC Edmonton and The Governors of the University of Alberta, which purported to terminate, effective December 12, 2017, the license agreement dated May 9, 2007 between the Company and The Governors of the University of Alberta. The license relates to the use of ampakines for the treatment of various respiratory disorders. The Company, through its counsel, disputed any grounds for termination and notified the representative that it invoked Section 13 of that license agreement, which mandates a meeting to be attended by individuals with decision-making authority to attempt in good faith to negotiate a resolution to the dispute. In February 2019, the Company and TEC Edmonton tentatively agreed to terms acceptable to all parties to establish a new license agreement and the form of a new license agreement. However, the Company has re-evaluated that portion of its ampakine program and has decided not to enter into a new agreement, at this time. The lack of entry into a new agreement at this time does not affect the Company’s other ampakine programs and permits the Company to reallocate resources to those programs, including, but not limited to ADHD, SCI, FXS and others. By e-mail dated July 21, 2016, the Company received a demand from an investment banking consulting firm that represented the Company in 2012 in conjunction with the Pier transaction alleging that $225,000 is due and payable for investment banking services rendered. Such amount has been included in accrued expenses at September 30, 2019 and December 31, 2018. The Company is periodically the subject of various pending and threatened legal actions and claims. In the opinion of management of the Company, adequate provision has been made in the Company’s consolidated financial statements as of September 30, 2019 and December 31, 2018 with respect to such matters, including, specifically, the matters noted above. The Company intends to vigorously defend itself if any of the matters described above results in the filing of a lawsuit or formal claim. Significant Agreements and Contracts Consulting Agreement Richard Purcell, the Company’s Senior Vice President of Research and Development since October 15, 2014, provides his services to the Company on a month-to-month basis through his consulting firm, DNA Healthlink, Inc., through which the Company has contracted for his services, for a monthly cash fee of $12,500. Additional information with respect to shares of common stock that have been issued to Mr. Purcell is provided at Note 6. Cash compensation expense pursuant to this agreement totaled $112,500 and $37,500 for the nine months and three months ended September 30, 2019 and 2018, which is included in research and development expenses in the Company’s consolidated statements of operations for such periods. Employment Agreements On October 12, 2018, Dr. Lippa was named Interim President and Interim Chief Executive Officer to replace Dr. Manuso who resigned effective September 30, 2018. Dr. Lippa continues to serve as the Company’s Executive Chairman and as a member of the Board of Directors. Also, on August 18, 2015, Dr. Lippa was named Chief Scientific Officer of the Company, and the Company entered into an employment agreement with Dr. Lippa in that capacity. Pursuant to the agreement, which is for an initial term through September 30, 2018 (and which automatically extended on September 30, 2018 and September 30, 2019 and will automatically extend annually, upon the same terms and conditions, for successive periods of one year, unless either party provides written notice of its intention not to extend the term of the agreement at least 90 days prior to the applicable renewal date), Dr. Lippa received an annual base salary of $300,000. Dr. Lippa is also eligible to earn a performance-based annual bonus award of up to 50% of his base salary, based upon the achievement of annual performance goals established by the Board of Directors in consultation with the executive prior to the start of such fiscal year, or any amount at the discretion of the Board of Directors. Additionally, Dr. Lippa was granted stock options to acquire 30,769 shares of common stock of the Company and is eligible to receive additional awards under the Company’s Plans at the discretion of the Board of Directors. Dr. Lippa is also entitled to receive, until such time as the Company establishes a group health plan for its employees, $1,200 per month, on a tax-equalized basis, as additional compensation to cover the cost of health coverage and up to $1,000 per month, on a tax-equalized basis, as reimbursement for a term life insurance policy and disability insurance policy. Dr. Lippa is also entitled to be reimbursed for business expenses. Additional information with respect to the stock options granted to Dr. Lippa is provided at Note 6. Cash compensation accrued pursuant to this agreement totaled $254,700 and $84,900 for the nine months and three months ended September 30, 2019 and 2018, respectively, and $339,600 for the fiscal year ended December 31, 2018 which amounts are included in accrued compensation and related expenses in the Company’s consolidated balance sheet at September 30, 2019 and December 31, 2018, and in research and development expenses in the Company’s consolidated statement of operations. Dr. Lippa does not receive any additional compensation for serving as Executive Chairman and on the Board of Directors. On August 18, 2015, the Company also entered into an employment agreement with Jeff E. Margolis, in his role as Vice President, Secretary and Treasurer. Pursuant to the agreement, which was for an initial term through September 30, 2016 (and which has automatically extended on each subsequent anniversary and will continue to automatically extend annually upon the same terms and conditions, for successive periods of one year, unless either party provides written notice of its intention not to extend the term of the agreement at least 90 days prior to the applicable renewal date). At the inception of the employment agreement, Mr. Margolis was granted stock options to acquire 30,769 shares of common stock of the Company and remians eligible to receive additional awards under the Company’s Plans at the discretion of the Board of Directors. Mr. Margolis is also entitled to receive, until such time as the Company establishes a group health plan for its employees, $1,200 per month, on a tax-equalized basis, as additional compensation to cover the cost of health coverage and up to $1,000 per month, on a tax-equalized basis, as reimbursement for a term life insurance policy and disability insurance policy. Mr. Margolis is also entitled to be reimbursed for business expenses. Mr. Margolis’ employment agreement was amended effective July 1, 2017. The employment agreement amendment called for payment in three installments in cash of the $60,000 bonus granted on June 30, 2015. A minimum of $15,000 was to be payable in cash as follows: (a) $15,000 payable in cash upon the next closing (after July 1, 2017) of any financing in excess of $100,000 (b) $15,000 payable by the end of the following month assuming cumulative closings (beginning with the closing that triggered (a)) in excess of $200,000 and (c) $30,000 payable in cash upon the next closing of any financing in excess of an additional $250,000. The conditions of (a), (b) and (c) above were met as of December 31, 2017, however Mr. Margolis has waived the Company’s obligation to make any payments of the cash bonus until the Board of Directors of the Company determines that sufficient capital has been raised by the Company or is otherwise available to fund the Company’s operations on an ongoing basis. Mr. Margolis currently receives an annual base salary of $300,000, and is also eligible to receive performance-based annual bonus awards ranging from $65,000 to $125,000, based upon the achievement of annual performance goals established by the Board of Directors in consultation with Mr. Margolis prior to the start of such fiscal year, or any amount at the discretion of the Board of Directors. Additional information with respect to the stock options granted to Mr. Margolis is provided at Note 6. Recurring cash compensation accrued pursuant to this amended agreement totaled $241,200 and $80,400 for the nine months and three months ended September 30, 2019 and 2018, respectively, and $321,600 for the fiscal year ended December 31, 2018. Such amounts are included in accrued compensation and related expenses in the Company’s consolidated balance sheet at September 30, 2019 and December 31, 2018 respectively, and in general and administrative expenses in the Company’s consolidated statement of operations. The employment agreements between the Company and each of Dr. Lippa and Mr. Margolis (prior to the 2017 amendment), respectively, provided that the payment obligations associated with the first year base salary were to accrue, but no payments were to be made, until at least $2,000,000 of net proceeds from any offering or financing of debt or equity, or a combination thereof, was received by the Company, at which time scheduled payments were to commence. Dr. Lippa and Mr. Margolis (who are each also directors of the Company), and prior to his resignation, Dr. James S. Manuso, have each agreed, effective as of August 11, 2016, to continue to defer the payment of such amounts indefinitely, until such time as the Board of Directors of the Company determines that sufficient capital has been raised by the Company or is otherwise available to fund the Company’s operations on an ongoing basis. Additionally, on December 9, 2017, Dr. Lippa, Mr. Margolis and Dr. Manuso forgave accrued compensation that had accrued through September 30, 2017 in exchange for stock options. University of Alberta License Agreement On May 9, 2007, the Company entered into a license agreement, as amended, with the University of Alberta granting the Company exclusive rights to practice patents held by the University of Alberta claiming the use of ampakines for the treatment of various respiratory disorders. The Company agreed to pay the University of Alberta a licensing fee and a patent issuance fee, which were paid, and prospective payments consisting of a royalty on net sales, sublicense fee payments, maintenance payments and milestone payments. The prospective maintenance payments commence on the enrollment of the first patient into the first Phase 2B clinical trial and increase upon the successful completion of the Phase 2B clinical trial. As the Company does not at this time anticipate scheduling a Phase 2B clinical trial in the near term, no maintenance payments to the University of Alberta are currently due and payable, nor are any maintenance payments expected to be due in the near future in connection with the license agreement. On May 18, 2018, the Company received a letter from counsel claiming to represent TEC Edmonton and The Governors of the University of Alberta, which purported to terminate, effective December 12, 2017, the license agreement dated May 9, 2007 (as subsequently amended) between the Company and The Governors of the University of Alberta. The Company, through its counsel, disputed any grounds for termination and notified the representative that it invoked Section 13 of that license agreement, which mandates a meeting to be attended by individuals with decision-making authority to attempt in good faith to negotiate a resolution to the dispute. In February 2019, the Company and TEC Edmonton tentatively agreed to terms acceptable to all parties to establish a new license agreement and the form of a new license agreement. However, the Company has re-evaluated that portion of its ampakine program and has decided not to enter into a new agreement, at this time. The lack of entry into a new agreement at this time does not affect the Company’s other ampakine programs and permits the Company to reallocate resources to those programs, including, but not limited to ADHD, SCI, FXS and others. University of Illinois 2014 Exclusive License Agreement On June 27, 2014, the Company entered into an Exclusive License Agreement (the “2014 License Agreement”) with the University of Illinois, the material terms of which were similar to a License Agreement between the parties that had been previously terminated on March 21, 2013. The 2014 License Agreement became effective on September 18, 2014, upon the completion of certain conditions set forth in the 2014 License Agreement, including: (i) the payment by the Company of a $25,000 licensing fee, (ii) the payment by the Company of outstanding patent costs aggregating $15,840, and (iii) the assignment to the University of Illinois of rights the Company held in certain patent applications, all of which conditions were fulfilled. The 2014 License Agreement granted the Company (i) exclusive rights to several issued and pending patents in numerous jurisdictions and (ii) the non-exclusive right to certain technical information that is generated by the University of Illinois in connection with certain clinical trials as specified in the 2014 License Agreement, all of which relate to the use of cannabinoids for the treatment of sleep related breathing disorders. The Company is developing dronabinol (Δ9-tetrahydrocannabinol), a cannabinoid, for the treatment of OSA, the most common form of sleep apnea. The 2014 License Agreement provides for various commercialization and reporting requirements commencing on June 30, 2015. In addition, the 2014 License Agreement provides for various royalty payments, including a royalty on net sales of 4%, payment on sub-licensee revenues of 12.5%, and a minimum annual royalty beginning in 2015 of $100,000, which is due and payable on December 31 of each year beginning on December 31, 2015. The minimum annual royalty obligation of $100,000 due on December 31, 2018, was extended to February 28, 2019, when such payment obligation was paid by the Company. One-time milestone payments may become due based upon the achievement of certain development milestones. $350,000 will be due within five days after the dosing of the first patient is a Phase III human clinical trial anywhere in the world. $500,000 will be due within five days after the first NDA filing with FDA or a foreign equivalent. $1,000,000 will be due within twelve months of the first commercial sale. One-time royalty payments may also become due and payable. Annual royalty payments may also become due. In the year after the first application for market approval is submitted to the FDA or a foreign equivalent and until approval is obtained, the minimum annual royalty will increase to $150,000. In the year after the first market approval is obtained from the FDA or a foreign equivalent and until the first sale of a product, the minimum annual royalty will increase to $200,000. In the year after the first commercial sale of a product, the minimum annual royalty will increase to $250,000. For each of the nine month and three month periods ending September 30, 2019 and 2018, the Company recorded a charge to operations of $75,000 and $25,000, respectively, with respect to its minimum annual royalty obligation, which is included in research and development expenses in the Company’s consolidated statements of operations for the nine months and three months ended September 30, 2019 and 2018, respectively. Research Contract with the University of Alberta On January 12, 2016, the Company entered into a Research Contract with the University of Alberta in order to test the efficacy of ampakines at a variety of dosage and formulation levels in the potential treatment of Pompe Disease, apnea of prematurity and spinal cord injury, as well as to conduct certain electrophysiological studies to explore the ampakine mechanism of action for central respiratory depression. The Company agreed to pay the University of Alberta total consideration of approximately CAD$146,000 (approximately US$111,000), consisting of approximately CAD$85,000 (approximately US$65,000) of personnel funding in cash in four installments during 2016, to provide approximately CAD$21,000 (approximately US$16,000) in equipment, to pay patent costs of CAD$20,000 (approximately US$15,000), and to underwrite additional budgeted costs of CAD$20,000 (approximately US$15,000). The final amount payable in respect to this Research Contract of US$16,207 (CAD$21,222) was paid in US dollars in January 2018 and completed the payments under the contract. The conversion to US dollars above utilizes an exchange rate of approximately US$0.76 for every CAD$1.00. The University of Alberta received matching funds through a grant from the Canadian Institutes of Health Research in support of this research. Dr. John Greer, faculty member of the Department of Physiology, Perinatal Research Centre and Women & Children’s Health Research Institute at the University of Alberta collaborated on this research. The studies were completed in 2016. See “University of Alberta License Agreement” above for more information on the related license agreement. Summary of Principal Cash Obligations and Commitments The following table sets forth the Company’s principal cash obligations and commitments for the next five fiscal years as of September 30, 2019, aggregating $1,211,200 License agreement amounts included in the 2019 column represents amounts contractually due from October 1, 2019 through December 31, 2019 (three months) and in each of the subsequent years, represents the full year. Employment agreement amounts included in the 2019 column represent amounts contractually due at from October 1, 2019 through September 30, 2020 (twelve months) when such contracts expire unless extended pursuant to the terms of the contracts. Payments Due By Year Total 2019 2020 2021 2022 2023 License agreements $ 425,000 $ 25,000 $ 100,000 $ 100,000 $ 100,000 $ 100,000 Litigation settlement 125,000 $ 125,000 - - - - Employment agreements (1) 661,200 165,300 495,900 - - - Total $ 1,211,200 $ 315,300 $ 595,900 $ 100,000 $ 100,000 $ 100,000 (1) The payment of such amounts has been deferred indefinitely, as described above at “Employment Agreements.” The 2019 amounts include three months of employment agreement obligations for Dr. Lippa and Mr. Margolis as their employment contracts renewed on September 30, 2019 and the 2019 obligations include the three months of obligations through December 31, 2019. |
Subsequent Events
Subsequent Events | 9 Months Ended |
Sep. 30, 2019 | |
Subsequent Events [Abstract] | |
Subsequent Events | 9. Subsequent Events On October 22, 2019, the Company entered into a securities purchase agreement, a 10% Convertible Note (the “October 2019 Convertible Note”) and several other related agreements and documents. The October 2019 Convertible Note matures on July 22, 2020, provided for net proceeds to the Company of $54,500 which was received by the Company on October 28, 2019, and has a face amount of $60,000, bears interest at 10% per year, had an original issue discount of $1,750 and capitalized note costs of $3,750 (for legal and due diligence fees of the Holder of the October 2019 Convertible Note). The holder of the October 2019 Convertible Note also received 10,000 restricted shares of the Company’s common stock as commitment shares and a warrant to purchase 175,000 shares of the Company’s common stock, exercisable at $0.50 per share of common stock for five years. The October 2019 Convertible Note may be prepaid at the option of the Company, inclusive of accrued interest, by the Company subject to prepayment premium factors as described in the definitive documents and may not be prepaid after the 180th day. Subject to certain limitations, the October 2019 Convertible Note may be converted by the holder at 60% of the lowest traded price of the Company’s common stock, subject to a minimum trade size of 100 shares and a minimum daily trading volume of at least 100 shares, for the twenty (20) consecutive trading days prior to such conversion. In addition, the holder has certain redemption rights in the event of a subsequent financing and other rights. Pursuant to the terms of the definitive transaction documents, the Company must reserve that number of shares of common stock from its authorized but unissued shares that is six (6) times the number of shares of common stock into which the October 2019 Convertible Note may convert. At inception the Company reserved 1,935,000 shares in connection with the transaction. On November 4, 2019, the Company entered into a securities purchase agreement, a 10% Convertible Note (the “November 2019 Convertible Note”) and several other related agreements and documents. The November 2019 Convertible Note has a face amount of $170,000, matures on November 4, 2020, bears interest at 10% per year and resulted in net proceeds to the Company of $147,900, after taking into account capitalized note costs of $8,500 and an original issue discount of $13,600. There were no warrants or commitment shares issued with respect to the November 2019 Convertible Note. The November 2019 Convertible Note may be prepaid subject to prepayment premium factors as described in the definitive documents and may not be prepaid after the 180th day. The holder may convert, at any time, the November 2019 Convertible Note at the holder’s option into shares of the Company’s common stock at a price that is 60% of the lowest trading price, taking into consideration only trades of 100 shares or more, for the twenty (20) consecutive trading days prior to and inclusive of the conversion date of such conversion. Pursuant to the terms of the definitive transaction documents, at inception, the Company created an initial reserve of 5,200,000 shares of common stock in connection with this transaction from its authorized but unissued shares and must maintain a reserve at all times that is five (5) times the number of shares of common stock into which the October 2019 Convertible Note may convert. On November 12, 2019 the holder of the April 2019 Convertible Note (See Note 4. Notes Payable - Convertible Notes Payable |
Summary of Significant Accoun_2
Summary of Significant Accounting Policies (Policies) | 9 Months Ended |
Sep. 30, 2019 | |
Accounting Policies [Abstract] | |
Principles of Consolidation | Principles of Consolidation The accompanying condensed consolidated financial statements are prepared in accordance with United States generally accepted accounting principles (“GAAP”) and include the financial statements of RespireRx and its wholly-owned subsidiary, Pier. Intercompany balances and transactions have been eliminated in consolidation. |
Use of Estimates | Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions. These estimates and assumptions affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include, among other things, accounting for potential liabilities, and the assumptions used in valuing stock-based compensation issued for services. Actual amounts may differ from those estimates. |
Concentration of Risk | Concentration of Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company limits its exposure to credit risk by investing its cash with high credit quality financial institutions. The Company’s research and development efforts and potential products rely on licenses from research institutions and if the Company loses access to these technologies or applications, its business could be substantially impaired. |
Cash Equivalents | Cash Equivalents The Company considers all highly liquid short-term investments with maturities of less than three-months when acquired to be cash equivalents. |
Fair Value of Financial Instruments | Fair Value of Financial Instruments The authoritative guidance with respect to fair value of financial instruments established a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three levels and requires that assets and liabilities carried at fair value be classified and disclosed in one of three categories, as presented below. Disclosure as to transfers into and out of Levels 1 and 2, and activity in Level 3 fair value measurements, is also required. Level 1. Observable inputs such as quoted prices in active markets for an identical asset or liability that the Company has the ability to access as of the measurement date. Financial assets and liabilities utilizing Level 1 inputs include active-exchange traded securities and exchange-based derivatives. Level 2. Inputs, other than quoted prices included within Level 1, which are directly observable for the asset or liability or indirectly observable through corroboration with observable market data. Financial assets and liabilities utilizing Level 2 inputs include fixed income securities, non-exchange based derivatives, mutual funds, and fair-value hedges. Level 3. Unobservable inputs in which there is little or no market data for the asset or liability which requires the reporting entity to develop its own assumptions. Financial assets and liabilities utilizing Level 3 inputs include infrequently-traded, non-exchange-based derivatives and commingled investment funds, and are measured using present value pricing models. The Company determines the level in the fair value hierarchy within which each fair value measurement falls in its entirety, based on the lowest level input that is significant to the fair value measurement in its entirety. In determining the appropriate levels, the Company performs an analysis of the assets and liabilities at each reporting period end. The carrying amounts of financial instruments (consisting of cash, cash equivalents, advances on research grants and accounts payable and accrued expenses) are considered by the Company to be representative of the respective fair values of these instruments due to the short-term nature of those instruments. With respect to the note payable to SY Corporation Co., Ltd., formerly known as Samyang Optics Co. Ltd. (“SY Corporation”) and the convertible notes payable, management does not believe that the credit markets have materially changed for these types of borrowings since the original borrowing date. The Company considers the carrying amounts of the notes payable to officers, inclusive of accrued interest, to be representative of the respective fair values of such instruments due to the short-term nature of those instruments and their terms. |
Convertible Notes Payable | Convertible Notes Payable Convertible notes are evaluated to determine if they should be recorded at amortized cost. To the extent that there are associated warrants or a beneficial conversion feature, the convertible notes and warrants are evaluated to determine if there are embedded derivatives to be identified, bifurcated and valued at fair value in connection with and at the time of such financing. The value of debt discounts such as warrants, beneficial conversion features and original issue discounts are recorded as contra debt and amortized into interest expense over the life of the notes. |
Extinguishment of Debt | Extinguishment of Debt The Company accounts for the extinguishment of debt in accordance with GAAP by comparing the carrying value of the debt to the fair value of consideration paid or assets given up and recognizing a loss or gain in the condensed consolidated statement of operations in the amount of the difference in the period in which such transaction occurs. |
Equipment | Equipment Equipment is recorded at cost and depreciated on a straight-line basis over their estimated useful lives, which range from three to five years. All equipment was fully depreciated as of September 30, 2019. |
Prepaid Insurance | Prepaid Insurance Long-term prepaid insurance represents the premium paid in March 2014 for directors’ and officers’ insurance tail coverage, which is being amortized on a straight-line basis over the policy period of six years. The amount amortizable in the ensuing twelve- month period is recorded as a current asset in the Company’s condensed consolidated balance sheet at each reporting date. As of September 30, 2019, all such prepaid amounts have been reclassified as current since the policy will expire within one year. |
Impairment of Long-lived Assets | Impairment of Long-Lived Assets The Company reviews its long-lived assets, including long-term prepaid insurance, for impairment whenever events or changes in circumstances indicate that the total amount of an asset may not be recoverable, but at least annually. An impairment loss is recognized when estimated future cash flows expected to result from the use of the asset and its eventual disposition is less than the asset’s carrying amount. The Company has not deemed any long-lived assets as impaired at September 30, 2019. |
Stock-based Awards | Stock-Based Awards The Company periodically issues common stock and stock options to officers, directors, outside consultants and vendors for services rendered. Such issuances vest and expire according to terms established at the issuance date of each grant. The Company accounts for stock-based payments to officers, directors, outside consultants and vendors by measuring the cost of services received in exchange for equity awards based on the grant date fair value of the awards, with the cost recognized as compensation expense on the straight-line basis in the Company’s consolidated financial statements over the vesting period of the awards. The fair value of stock options granted as stock-based payments is determined utilizing the Black-Scholes option-pricing model, and is affected by several variables, the most significant of which are the life of the equity award, the exercise price of the stock option as compared to the fair market value of the common stock on the grant date, and the estimated volatility of the common stock over the term of the equity award. Estimated volatility is based on the historical volatility of the Company’s common stock. The risk- free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant. The fair market value of common stock is determined by reference to the quoted market price of the Company’s common stock. There were no stock or stock option grants during the nine months ended September 30, 2019. For stock options requiring an assessment of value during the nine months ended September 30, 2018, the fair value of each stock option award was estimated using the Black-Scholes option-pricing model using the following assumptions: Risk-free interest rate 2.56 % Expected dividend yield 0 % Expected volatility 185.41 % Expected life 4.5 The Company recognizes the fair value of stock-based payments in general and administrative costs and in research and development costs, as appropriate, in the Company’s condensed consolidated statements of operations. The Company issues new shares of common stock to satisfy stock option and warrant exercises. There were no stock options exercised during the nine months ended September 30, 2019 and 2018. |
Income Taxes | Income Taxes The Company accounts for income taxes under an asset and liability approach for financial accounting and reporting for income taxes. Accordingly, the Company recognizes deferred tax assets and liabilities for the expected impact of differences between the financial statements and the tax basis of assets and liabilities. The Company records a valuation allowance to reduce its deferred tax assets to the amount that is more likely than not to be realized. In the event the Company was to determine that it would be able to realize its deferred tax assets in the future in excess of its recorded amount, an adjustment to the deferred tax assets would be credited to operations in the period such determination was made. Likewise, should the Company determine that it would not be able to realize all or part of its deferred tax assets in the future, an adjustment to the deferred tax assets would be charged to operations in the period such determination was made. Pursuant to Internal Revenue Code Sections 382 and 383, use of the Company’s net operating loss and credit carryforwards may be limited if a cumulative change in ownership of more than 50% occurs within any three-year period since the last ownership change. The Company may have had a change in control under these Sections. However, the Company does not anticipate performing a complete analysis of the limitation on the annual use of the net operating loss and tax credit carryforwards until the time that it anticipates it will be able to utilize these tax attributes. As of September 30, 2019, the Company did not have any unrecognized tax benefits related to various federal and state income tax matters and does not anticipate any material amount of unrecognized tax benefits within the next 12 months. The Company is subject to U.S. federal income taxes and income taxes of various state tax jurisdictions. As the Company’s net operating losses have yet to be utilized, all previous tax years remain open to examination by Federal authorities and other jurisdictions in which the Company currently operates or has operated in the past. The Company accounts for uncertainties in income tax law under a comprehensive model for the financial statement recognition, measurement, presentation and disclosure of uncertain tax positions taken or expected to be taken in income tax returns as prescribed by GAAP. The tax effects of a position are recognized only if it is “more-likely-than-not” to be sustained by the taxing authority as of the reporting date. If the tax position is not considered “more-likely-than-not” to be sustained, then no benefits of the position are recognized. As of September 30, 2019, the Company had not recorded any liability for uncertain tax positions. In subsequent periods, any interest and penalties related to uncertain tax positions will be recognized as a component of income tax expense. |
Foreign Currency Transactions | Foreign Currency Transactions The note payable to SY Corporation, which is denominated in a foreign currency (the South Korean Won), is translated into the Company’s functional currency (the United States Dollar) at the exchange rate on the balance sheet date. The foreign currency exchange gain or loss resulting from translation is recognized in the related condensed consolidated statements of operations. |
Research and Development | Research and Development Research and development costs include compensation paid to management directing the Company’s research and development activities, and fees paid to consultants and outside service providers and organizations (including research institutes at universities), and other expenses relating to the acquisition, design, development and clinical testing of the Company’s treatments and product candidates. Research and development costs incurred by the Company under research grants are expensed as incurred over the life of the underlying contracts, unless the terms of the contract indicate that a different expensing schedule is more appropriate. The Company reviews the status of its research and development contracts on a quarterly basis. On May 6, 2016, the Company made an advance payment to Duke University with respect to the Phase 2A clinical trial of CX1739. At September 30, 2019, an asset balance of $48,912 remained from the advance payment. |
License Agreements | License Agreements Obligations incurred with respect to mandatory payments provided for in license agreements are recognized ratably over the appropriate period, as specified in the underlying license agreement, and are recorded as liabilities in the Company’s condensed consolidated balance sheet, with a corresponding charge to research and development costs in the Company’s condensed consolidated statement of operations. Obligations incurred with respect to milestone payments provided for in license agreements are recognized when it is probable that such milestone will be reached and are recorded as liabilities in the Company’s condensed consolidated balance sheet, with a corresponding charge to research and development costs in the Company’s condensed consolidated statement of operations. Payments of such liabilities are made in the ordinary course of business. |
Patent Costs | Patent Costs Due to the significant uncertainty associated with the successful development of one or more commercially viable products based on the Company’s research efforts and any related patent applications, all patent costs, including patent-related legal and filing fees, are expensed as incurred and recorded as general and administrative expenses. |
Earnings Per Share | Earnings per Share The Company’s computation of earnings per share (“EPS”) includes basic and diluted EPS. Basic EPS is measured as the income (loss) attributable to common stockholders divided by the weighted average common shares outstanding for the period. Diluted EPS is similar to basic EPS but presents the dilutive effect on a per share basis of potential common shares (e.g., warrants and options) as if they had been converted at the beginning of the periods presented, or issuance date, if later. Potential common shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share) are excluded from the calculation of diluted EPS. Loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the respective periods. Basic and diluted loss per common share is the same for all periods presented because all warrants and stock options outstanding are anti-dilutive. At September 30, 2019 and 2018, the Company excluded the outstanding securities summarized below, which entitle the holders thereof to acquire shares of common stock, from its calculation of earnings per share, as their effect would have been anti-dilutive. September 30, 2019 2018 Series B convertible preferred stock 11 11 Convertible notes payable 867,200 16,061 Common stock warrants 2,016,043 1,703,229 Common stock options 4,287,609 4,323,317 Total 7,170,863 5,507,312 |
Reclassifications | Reclassifications Certain comparative figures in 2018 have been reclassified to conform to the current nine month and three month presentation. These reclassifications were immaterial, both individually and in the aggregate. |
Recent Accounting Pronouncements | Recent Accounting Pronouncements From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that are adopted by the Company as of the specified effective date. Unless otherwise discussed, we believe that the impact of recently issued standards that are not yet effective will not have a material impact on our financial position or results of operations upon adoption. |
Summary of Significant Accoun_3
Summary of Significant Accounting Policies (Tables) | 9 Months Ended |
Sep. 30, 2019 | |
Accounting Policies [Abstract] | |
Summary of Fair Value of Option Estimated Using Black-Scholes Pricing Model with Valuation Assumptions | For stock options requiring an assessment of value during the nine months ended September 30, 2018, the fair value of each stock option award was estimated using the Black-Scholes option-pricing model using the following assumptions: Risk-free interest rate 2.56 % Expected dividend yield 0 % Expected volatility 185.41 % Expected life 4.5 |
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share | At September 30, 2019 and 2018, the Company excluded the outstanding securities summarized below, which entitle the holders thereof to acquire shares of common stock, from its calculation of earnings per share, as their effect would have been anti-dilutive. September 30, 2019 2018 Series B convertible preferred stock 11 11 Convertible notes payable 867,200 16,061 Common stock warrants 2,016,043 1,703,229 Common stock options 4,287,609 4,323,317 Total 7,170,863 5,507,312 |
Notes Payable (Tables)
Notes Payable (Tables) | 9 Months Ended |
Sep. 30, 2019 | |
Schedule of Convertible Notes Payable | The 2018 Convertible Notes and 2019 Q1 Convertible Notes consist of the following at September 30, 2019 and December 31, 2018: September 30, December 31, Principal amount of notes payable $ 190,000 $ 80,000 Discount associated with issuance of warrants net of amortization of $82,159 as of September 30, 2019 and $8,379 as of December 31,2018 - (27,968 ) Accrued interest payable 13,121 401 $ 203,121 $ 52,433 The remaining outstanding Original Convertible Notes (including those for which default notices have been received) consist of the following at September 30, 2019 and December 31, 2018: September 30, December 31, Principal amount of notes payable $ 125,000 $ 125,000 Accrued interest payable 76,920 62,233 $ 201,920 $ 187,233 |
Summary of Note Payable to Related Party | Note payable to SY Corporation consists of the following at September 30, 2019 and December 31, 2018: September 30, December 31, Principal amount of note payable $ 399,774 $ 399,774 Accrued interest payable 351,188 315,307 Foreign currency transaction adjustment (27,775 ) 29,360 $ 723,187 $ 744,441 |
August 2019 Convertible Note [Member] | |
Schedule of Convertible Notes Payable | The table below provides a summary of the August 2019 Convertible Note as of September 30, 2019. Principal amount of note payable $ 55,000 Debt discounts, net of amortization of $8,504 (46,496 ) Accrued coupon interest 648 $ 9,152 |
May 2019 Convertible Note [Member] | |
Schedule of Convertible Notes Payable | The table below provides a summary of the May 2019 Convertible Note as of September 30, 2019. Principal amount of note payable $ 50,000 Debt discounts, net of amortization of $19,072 (31,149 ) Accrued coupon interest 1,876 $ 20,727 |
April 2019 Convertible Note [Member] | |
Schedule of Convertible Notes Payable | The table below provides a summary of the April 2019 Convertible Note as of September 30, 2019. Principal amount of note payable $ 58,500 Debt discounts, net of amortization of $21,238 (27,211 ) Accrued coupon interest 2,859 $ 34,148 |
Stockholders' Deficiency (Table
Stockholders' Deficiency (Tables) | 9 Months Ended |
Sep. 30, 2019 | |
Equity [Abstract] | |
Schedule of Warrants Activity | A summary of warrant activity for the nine months ended September 30, 2019 is presented below. Weighted Average Weighted Remaining Number of Average Contractual Shares Exercise Price Life (in Years) Warrants outstanding and exerciable at December 31, 2018 1,783,229 $ 2.20393 3.06 Issued 302,372 0.95908 Expired (69,558 ) 2.65928 Warrants outstanding and exercisable at September 30, 2019 2,016,043 $ 1.99011 2.73 A summary of warrant activity for the nine months ended September 30, 2018 is presented below. Number of Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Life (in Years) Warrants outstanding and exercisable at December 31, 2017 1,464,415 $ 2.68146 3.73 Issued 238,814 1.57500 Warrants outstanding and exercisable at September 30, 2018 1,703,229 $ 2.52632 4.08 |
Summary of Stock Option Activity | A summary of stock option activity for the nine months ended September 30, 2019 is presented below. Number of Weighted Weighted Options outstanding and exercisable at December 31, 2018 4,344,994 $ 3.7634 7.38 Expired (57,385 ) (15.6139 ) Options outstanding and exercisable at September 30, 2019 4,287,609 $ 3.3798 5.23 A summary of stock option activity for the nine months ended September 30, 2018 is presented below. Number of Weighted Weighted Options outstanding and exercisable at December 31, 2017 3,996,167 $ 3.7634 6.30 Granted 327,150 1.1267 4.50 Options outstanding and exercisable at September 30, 2018 4,323,317 $ 3.5855 6.17 |
Schedule of Exercise Prices of Common Stock Warrants Outstanding and Exercisable | The exercise prices of common stock warrants outstanding and exercisable are as follows at September 30, 2019: Exercise Price Warrants (Shares) Warrants (Shares) Expiration Date $ 0.5000 150,000 150,000 August 19, 2024 $ 1.0000 916,217 916,217 September 20, 2022 $ 1.1800 42,372 42,372 May 17, 2022 $ 1.5000 190,000 190,000 December 30, 2023 $ 1.5620 130,284 130,284 December 31, 2021 $ 1.5750 238,814 238,814 April 30, 2023 $ 2.7500 8,000 8,000 September 20, 2022 $ 4.8750 108,594 108,594 September 30, 2020 $ 6.8348 145,758 145,758 September 30, 2020 $ 7.9300 86,004 86,004 February 28, 2021 2,016,043 2,016,043 The exercise prices of common stock warrants outstanding and exercisable are as follows at September 30, 2018: Exercise Price Warrants Outstanding Warrants Exercisable Expiration Date $ 1.0000 916,217 916,217 September 20, 2022 $ 1.2870 41,002 41,002 April 17, 2019 $ 1.5620 130,284 130,284 December 31, 2021 $ 1,5750 238,814 238,814 April 30, 2023 $ 2.7500 8,000 8000 September 20, 2022 $ 4.8500 5,155 5,155 September 23, 2019 $ 4.8750 108,594 108,594 September 30, 2020 $ 5.0000 5,000 5,000 September 22, 2019 $ 5.1025 10,309 10,309 January 29, 2019 $ 6.5000 8,092 8,092 February 4, 2019 $ 6.8348 145,758 145,758 September 30, 2020 $ 7.9300 86,004 86,004 February 28, 2021 1,703,229 1,703,229 |
Schedule of Exercise Prices of Common Stock Options Outstanding and Exercisable | The exercise prices of common stock options outstanding and exercisable were as follows at September 30, 2019: Exercise Price Options Outstanding Options Exercisable Expiration Date $ 0.7000 21,677 21,677 November 21, 2023 $ 1.1200 310,388 310,388 April 5, 2023 $ 1.2500 16,762 16,762 December 7, 2022 $ 1.3500 34,000 34,000 July 28, 2022 $ 1.4500 1,849,418 1,849,418 December 9, 2027 $ 1.4500 100,000 100,000 December 9, 2027 $ 2.0000 285,000 285,000 June 30, 2022 $ 2.0000 25,000 25,000 July 26, 2022 $ 3.9000 395,000 395,000 January 17, 2022 $ 4.5000 7,222 7,222 September 2, 2021 $ 5.6875 89,686 89,686 June 30, 2020 $ 5.7500 2,608 2,608 September 12, 2021 $ 6.4025 27,692 27,692 August 18, 2020 $ 6.4025 129,231 129,231 August 18, 2022 $ 6.4025 261,789 261,789 August 18, 2025 $ 6.8250 8,791 8,791 December 11, 2020 $ 7.3775 523,077 523,077 March 31, 2021 $ 8.1250 169,231 169,231 June 30, 2022 $ 13.9750 3,385 3,385 March 14, 2024 $ 15.4700 7,755 7,755 April 8, 2020 $ 15.9250 2,462 2,462 February 28, 2024 $ 16.6400 1,538 1,538 January 29, 2020 $ 19.5000 9,487 9,487 July 17, 2022 $ 19.5000 6,410 6,410 August 10, 2022 4,287,609 4,287,609 The exercise prices of common stock options outstanding and exercisable were as follows at September 30, 2018: Exercise Price Options Outstanding Options Exercisable Expiration Date $ 1.1200 310,388 310,388 April 5, 2023 $ 1.2500 16,762 16,762 December 7, 2022 $ 1.3500 34,000 34,000 July 28, 2022 $ 1.4500 1,849,418 1,849,418 December 9, 2027 $ 1.4500 100,000 100,000 December 9, 2027 $ 2.0000 285,000 285,000 June 30, 2022 $ 2.0000 25,000 25,000 July 26, 2022 $ 3.9000 395,000 395,000 January 17, 2022 $ 4.5000 7,222 7,222 September 2, 2021 $ 5.6875 89,686 89,686 June 30, 2020 $ 5.7500 2,608 2,608 September 12, 2021 $ 6.4025 27,692 27,692 August 18, 2020 $ 6.4025 129,231 129,231 August 18, 2022 $ 6.4025 261,789 261,789 August 18, 2025 $ 6.8250 8,791 8,791 December 11, 2020 $ 7.3775 523,077 523,077 March 31, 2021 $ 8.1250 169,231 169,231 June 30, 2022 $ 13.0000 7,385 7,385 March 13, 2019 $ 13.0000 3,846 3,846 April 14, 2019 $ 13.9750 3,385 3,385 March 14, 2024 $ 15.4700 7,755 7,755 April 8, 2020 $ 15.9250 2,462 2,462 February 28, 2024 $ 16.0500 46,154 46,154 July 17, 2019 $ 16.6400 1,538 1,538 January 29, 2020 $ 19.5000 9,487 9,487 July 17, 2022 $ 19.5000 6,410 6,410 August 10, 2022 4,323,317 4,323,317 |
Commitments and Contingencies (
Commitments and Contingencies (Tables) | 9 Months Ended |
Sep. 30, 2019 | |
Commitments and Contingencies Disclosure [Abstract] | |
Summary of Principal Cash Obligations and Commitments | Employment agreement amounts included in the 2019 column represent amounts contractually due at from October 1, 2019 through September 30, 2020 (twelve months) when such contracts expire unless extended pursuant to the terms of the contracts. Payments Due By Year Total 2019 2020 2021 2022 2023 License agreements $ 425,000 $ 25,000 $ 100,000 $ 100,000 $ 100,000 $ 100,000 Litigation settlement 125,000 $ 125,000 - - - - Employment agreements (1) 661,200 165,300 495,900 - - - Total $ 1,211,200 $ 315,300 $ 595,900 $ 100,000 $ 100,000 $ 100,000 (1) The payment of such amounts has been deferred indefinitely, as described above at “Employment Agreements.” The 2019 amounts include three months of employment agreement obligations for Dr. Lippa and Mr. Margolis as their employment contracts renewed on September 30, 2019 and the 2019 obligations include the three months of obligations through December 31, 2019. |
Business (Details Narrative)
Business (Details Narrative) - USD ($) | 3 Months Ended | 9 Months Ended | 12 Months Ended | |||||||
Sep. 30, 2019 | Jun. 30, 2019 | Mar. 31, 2019 | Sep. 30, 2018 | Jun. 30, 2018 | Mar. 31, 2018 | Sep. 30, 2019 | Sep. 30, 2018 | Dec. 31, 2018 | Dec. 31, 2017 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | ||||||||||
Net losses | $ 469,844 | $ 477,213 | $ 540,332 | $ 535,774 | $ 635,363 | $ 746,679 | $ 1,487,389 | $ 1,917,817 | $ 2,591,790 | |
Negative operating cash flows | 313,691 | 199,966 | 427,368 | |||||||
Cash and cash equivalents | 94 | 94 | 33,284 | |||||||
Stockholders' deficiency | $ 7,039,381 | $ 6,617,038 | $ 6,227,775 | $ 5,359,154 | $ 5,069,128 | $ 4,977,254 | $ 7,039,381 | $ 5,359,154 | $ 5,733,255 | $ 4,355,384 |
Summary of Significant Accoun_4
Summary of Significant Accounting Policies (Details Narrative) - USD ($) | 9 Months Ended | ||
Sep. 30, 2019 | Sep. 30, 2018 | Dec. 31, 2018 | |
Number of stock or stock options granted | 327,150 | ||
Stock options exercised | |||
Advance payment on research contract | $ 48,912 | $ 48,912 | |
Minimum [Member] | |||
Estimated useful lives of equipment | P3Y | ||
Maximum [Member] | |||
Estimated useful lives of equipment | P5Y |
Summary of Significant Accoun_5
Summary of Significant Accounting Policies - Summary of Fair Value of Option Estimated Using Black-Scholes Pricing Model with Valuation Assumptions (Details) | 9 Months Ended |
Sep. 30, 2019 | |
Accounting Policies [Abstract] | |
Risk-free interest rate | 2.56% |
Expected dividend yield | 0.00% |
Expected volatility | 185.41% |
Expected life | 4 years 6 months |
Summary of Significant Accoun_6
Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares | 9 Months Ended | |
Sep. 30, 2019 | Sep. 30, 2018 | |
Antidilutive Securities Excluded from Computation of Earnings Per Share | 7,170,863 | 5,507,312 |
Common Stock Warrants [Member] | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share | 2,016,043 | 1,703,229 |
Common Stock Options [Member] | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share | 4,287,609 | 4,323,317 |
Convertible Notes Payable [Member] | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share | 867,200 | 16,061 |
Series B Convertible Preferred Stock [Member] | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share | 11 | 11 |
Notes Payable (Details Narrativ
Notes Payable (Details Narrative) | Aug. 19, 2019USD ($)TradingDays$ / sharesshares | May 17, 2019USD ($)TradingDays$ / sharesshares | Apr. 24, 2019USD ($)TradingDays$ / sharesshares | Mar. 14, 2019USD ($) | Mar. 06, 2019USD ($) | Feb. 27, 2019USD ($) | Jan. 02, 2019USD ($) | Jun. 25, 2012USD ($) | Sep. 30, 2019USD ($)$ / sharesshares | Sep. 30, 2018USD ($) | Sep. 30, 2019USD ($)$ / sharesshares | Sep. 30, 2018USD ($) | Dec. 31, 2018USD ($)$ / sharesshares | Dec. 31, 2015USD ($)$ / sharesshares | Dec. 31, 2014USD ($)$ / sharesshares | Jun. 25, 2012KRW (₩) |
Debt instrument interest rate | 10.00% | 10.00% | ||||||||||||||
Debt maturity date | Jun. 25, 2013 | |||||||||||||||
Debt instrument original issue discount | $ 104,858 | $ 104,858 | $ 27,969 | |||||||||||||
Common stock, par value | $ / shares | $ 0.001 | $ 0.001 | $ 0.001 | |||||||||||||
Initial value of note | $ 42,406 | $ 42,406 | $ 38,292 | |||||||||||||
Interest expense | 70,168 | $ 35,161 | 221,813 | $ 96,230 | ||||||||||||
Accrued interest | 17,406 | 17,406 | 13,292 | |||||||||||||
Stockholder's percentage | 20.00% | 20.00% | ||||||||||||||
Percentage of convertible notes payable | 12.00% | 12.00% | ||||||||||||||
SY Corporation [Member] | ||||||||||||||||
Debt face amount | $ 400,000 | |||||||||||||||
Interest expense | 12,092 | 12,092 | 35,881 | 35,881 | ||||||||||||
SY Corporation [Member] | Won [Member] | ||||||||||||||||
Debt face amount | ₩ | ₩ 465,000,000 | |||||||||||||||
Dr. Arnold S [Member] | ||||||||||||||||
Interest expense | 2,589 | 3,319 | 7,683 | 9,517 | ||||||||||||
Dr. James S. Manuso [Member] | ||||||||||||||||
Interest expense | $ 3,886 | $ 3,564 | $ 11,530 | $ 9,754 | ||||||||||||
Warrant [Member] | ||||||||||||||||
Debt instrument interest rate | 8.89% | |||||||||||||||
Convertible Notes Payable [Member] | ||||||||||||||||
Warrant to purchase shares | shares | 27,936 | 27,936 | ||||||||||||||
Warrant exercise price | $ / shares | $ 11.375 | $ 11.375 | ||||||||||||||
Extended maturity date | Sep. 15, 2016 | Sep. 15, 2016 | ||||||||||||||
Accrued interest | $ 95,425 | $ 95,425 | $ 62,635 | |||||||||||||
Nine Monthly Installments [Member] | ||||||||||||||||
Debt periodic payments | 7,120 | |||||||||||||||
August 2019 Convertible Note [Member] | ||||||||||||||||
Debt issuance costs | $ 2,500 | |||||||||||||||
Debt instrument original issue discount | $ 5,000 | 46,496 | 46,496 | |||||||||||||
Warrant to purchase shares | shares | 150,000 | |||||||||||||||
Commitment shares | shares | 7,500 | |||||||||||||||
Proceeds from convertible debt | $ 47,500 | |||||||||||||||
Debt instrument, convertible, conversion price | $ / shares | $ 0.50 | |||||||||||||||
Debt instrument, convertible, closing price | $ / shares | $ 0.50 | |||||||||||||||
Debt instrument, conversion percentage | 0.60 | |||||||||||||||
Debt instrument, convertible, threshold trading days | TradingDays | 20 | |||||||||||||||
Debt conversion, description | Subject to certain limitations and adjustments as described in the August 2019 Convertible Note, the holder may convert the August 2019 Convertible Note at a fixed conversion price of $0.50 per share of common stock, provided that from the date that is six months after the issuance date, the conversion price shall be the lower of (a) $0.50 or (b) 60% multiplied by the lowest closing price of the common stock during the twenty (20) consecutive trading days prior to conversion. The Company evaluated all of the terms of the August 2019 Convertible Note and determined that, in accordance with ASC 815, there were no derivatives to be bifurcated or separately valued. However, there were five features of the August 2019 Convertible Note and the related securities purchase agreement that required valuation. They were: (i) the debt issuance costs of $2,500, (ii) the intrinsic value of the beneficial conversion feature, (iii) the value of the warrant, (iv) the original issue discount of $5,000, and (v) the value of the Commitment Shares. The Company amortizes each of these five on a straight-line basis over the life of the August 2019 Convertible Note. | |||||||||||||||
Debt beneficial conversion feature | $ 16,500 | |||||||||||||||
Shares issued price per share | $ / shares | $ 0.65 | |||||||||||||||
Warrant term | 5 years | |||||||||||||||
Value of warrants to purchase shares | $ 93,450 | |||||||||||||||
Warrant fair value | 30,440 | |||||||||||||||
Commitment shares fair value | $ 1,588 | |||||||||||||||
August 2019 Convertible Note [Member] | Warrant [Member] | ||||||||||||||||
Debt instrument interest rate | 64.08% | |||||||||||||||
August 2019 Convertible Note [Member] | Commitment Shares [Member] | ||||||||||||||||
Debt instrument interest rate | 3.34% | |||||||||||||||
August 2019 Convertible Note [Member] | One Warrant [Member] | ||||||||||||||||
Warrant exercise price | $ / shares | $ 0.623 | |||||||||||||||
August 2019 Convertible Note [Member] | Risk Free Interest Rate [Member] | ||||||||||||||||
Warrants and rights outstanding, measurement input | 1.47 | |||||||||||||||
August 2019 Convertible Note [Member] | Measurement Input, Volatility [Member] | ||||||||||||||||
Warrants and rights outstanding, measurement input | 175.5 | |||||||||||||||
August 2019 Convertible Note [Member] | Tranches [Member] | ||||||||||||||||
Debt instrument interest rate | 10.00% | |||||||||||||||
Debt face amount | $ 55,000 | |||||||||||||||
Debt maturity date | May 19, 2020 | |||||||||||||||
May 2019 Convertible Note [Member] | ||||||||||||||||
Debt instrument interest rate | 13.56% | |||||||||||||||
Debt issuance costs | $ 2,000 | |||||||||||||||
Debt instrument original issue discount | 5,000 | $ 31,149 | $ 31,149 | |||||||||||||
Proceeds from convertible debt | $ 43,000 | |||||||||||||||
Debt instrument, convertible, conversion price | $ / shares | $ 0.25 | |||||||||||||||
Debt instrument, convertible, closing price | $ / shares | $ 0.25 | |||||||||||||||
Debt instrument, conversion percentage | 0.61 | |||||||||||||||
Debt instrument, convertible, threshold trading days | TradingDays | 25 | |||||||||||||||
Debt beneficial conversion feature | $ 286,000 | |||||||||||||||
Warrant exercise price | $ / shares | $ 1.18 | |||||||||||||||
Shares issued price per share | $ / shares | $ 0.84 | |||||||||||||||
Warrant term | 3 years | |||||||||||||||
Warrant fair value | $ 32,796 | |||||||||||||||
Warrant exercisable, shares | shares | 42,373 | |||||||||||||||
May 2019 Convertible Note [Member] | One Warrant [Member] | ||||||||||||||||
Shares issued price per share | $ / shares | $ 0.774 | |||||||||||||||
May 2019 Convertible Note [Member] | Risk Free Interest Rate [Member] | ||||||||||||||||
Warrants and rights outstanding, measurement input | 2.15 | |||||||||||||||
May 2019 Convertible Note [Member] | Measurement Input, Volatility [Member] | ||||||||||||||||
Warrants and rights outstanding, measurement input | 210.19 | |||||||||||||||
May 2019 Convertible Note [Member] | Tranches [Member] | ||||||||||||||||
Debt instrument interest rate | 10.00% | |||||||||||||||
May 2019 Convertible Note [Member] | Tranches [Member] | Maximum [Member] | ||||||||||||||||
Debt face amount | $ 150,000 | |||||||||||||||
May 2019 Convertible Note [Member] | Tranche One [Member] | ||||||||||||||||
Debt face amount | $ 50,000 | |||||||||||||||
Debt maturity date | May 17, 2020 | |||||||||||||||
Debt instrument, convertible, conversion price | $ / shares | $ 0.125 | $ 0.175 | $ 0.175 | |||||||||||||
Debt instrument, conversion percentage | 0.50 | |||||||||||||||
Converted into common stock | shares | 400,000 | 296,438 | ||||||||||||||
Common stock, par value | $ / shares | $ 0.001 | |||||||||||||||
Beneficial Conversion Feature [Member] | ||||||||||||||||
Debt instrument interest rate | 77.55% | |||||||||||||||
April 2019 Convertible Note [Member] | ||||||||||||||||
Debt instrument interest rate | 10.00% | |||||||||||||||
Debt face amount | $ 58,500 | |||||||||||||||
Debt maturity date | Apr. 24, 2020 | |||||||||||||||
Debt issuance costs | $ 3,500 | |||||||||||||||
Debt instrument original issue discount | $ 27,211 | $ 27,211 | ||||||||||||||
Proceeds from convertible debt | $ 50,000 | |||||||||||||||
Debt instrument, convertible, conversion price | $ / shares | $ 0.3964 | |||||||||||||||
Debt instrument, convertible, closing price | $ / shares | $ 0.65 | |||||||||||||||
Debt instrument, conversion percentage | 0.61 | |||||||||||||||
Debt instrument, convertible, threshold trading days | TradingDays | 20 | |||||||||||||||
Debt beneficial conversion feature | $ 44,950 | |||||||||||||||
Converted into common stock | shares | 147,541 | |||||||||||||||
2019 Q1 Convertible Notes [Member] | ||||||||||||||||
Debt instrument interest rate | 10.00% | 10.00% | 10.00% | 10.00% | 10.00% | 10.00% | ||||||||||
Debt face amount | $ 100,000 | $ 100,000 | $ 100,000 | $ 10,000 | ||||||||||||
Debt maturity date | Apr. 30, 2019 | Apr. 30, 2019 | Apr. 30, 2019 | Feb. 28, 2019 | Feb. 28, 2019 | |||||||||||
Debt instrument original issue discount | $ 45,812 | $ 45,812 | ||||||||||||||
Warrant to purchase shares | shares | 110,000 | 110,000 | ||||||||||||||
Warrant exercise price | $ / shares | $ 1.50 | $ 1.50 | ||||||||||||||
Value of warrants to purchase shares | $ 78,780 | $ 78,780 | ||||||||||||||
Fair value of convertible note and warrant | 188,780 | |||||||||||||||
Initial value of note | 64,188 | 64,188 | ||||||||||||||
Additional debt interest expense | $ 2,811 | $ 6,653 | ||||||||||||||
Debt instrument, description | The 2019 Convertible Note that matured on February 28, 2019 was not paid and remains outstanding and continues to accrue interest. The 2019 Convertible Notes that matured on April 30, 2019 were not paid and remain outstanding and continue to accrue interest. | |||||||||||||||
2018 Convertible Notes [Member] | Investor [Member] | ||||||||||||||||
Debt instrument interest rate | 10.00% | 10.00% | 10.00% | |||||||||||||
Debt face amount | $ 80,000 | |||||||||||||||
Debt maturity date | Feb. 28, 2019 | |||||||||||||||
Debt instrument original issue discount | $ 36,347 | |||||||||||||||
Warrant to purchase shares | shares | 80,000 | |||||||||||||||
Warrant exercise price | $ / shares | $ 1.50 | |||||||||||||||
Value of warrants to purchase shares | $ 68,025 | |||||||||||||||
Fair value of convertible note and warrant | 148,025 | |||||||||||||||
Initial value of note | 43,653 | |||||||||||||||
Additional debt interest expense | $ 2,044 | $ 6,067 | ||||||||||||||
Convertible Notes Payable [Member] | Investor [Member] | ||||||||||||||||
Debt instrument interest rate | 10.00% | 10.00% | ||||||||||||||
Debt face amount | $ 579,500 | $ 579,500 | ||||||||||||||
Warrant to purchase shares | shares | 50,945 | 50,945 | ||||||||||||||
Warrant exercise price | $ / shares | $ 11.3750 | $ 11.3750 | ||||||||||||||
Convertible Notes [Member] | ||||||||||||||||
Debt instrument interest rate | 12.00% | 12.00% | ||||||||||||||
Debt periodic payments | $ 42,406 | 38,292 | ||||||||||||||
Accrued interest | $ 17,406 | $ 17,406 | $ 13,292 | |||||||||||||
Original Convertible Notes [Member] | ||||||||||||||||
Converted into common stock | shares | 17,810 | 16,460 | ||||||||||||||
Accrued interest | $ 76,920 | $ 76,920 | $ 62,233 | |||||||||||||
Number of conversion into common shares attributable to accrued interest | shares | 6,765 | 5,471 | ||||||||||||||
Other Short-Term Notes Payable [Member] | ||||||||||||||||
Debt instrument interest rate | 9.00% | 9.00% | ||||||||||||||
Insurance premium | $ 61,746 | $ 61,746 | ||||||||||||||
Short term borrowings | $ 27,997 | $ 27,997 | $ 8,907 |
Notes Payable - Schedule of Con
Notes Payable - Schedule of Convertible Notes Payable (Details) - USD ($) | Sep. 30, 2019 | Aug. 19, 2019 | May 17, 2019 | Dec. 31, 2018 |
Debt discounts, net of amortization | $ (104,858) | $ (27,969) | ||
Accrued interest payable | 17,406 | 13,292 | ||
Convertible notes payable, gross | 469,067 | 239,666 | ||
August 2019 Convertible Note [Member] | ||||
Principal amount of notes payable | 55,000 | |||
Debt discounts, net of amortization | (46,496) | $ (5,000) | ||
Accrued coupon interest | 648 | |||
Convertible notes payable, gross | 9,152 | |||
May 2019 Convertible Note [Member] | ||||
Principal amount of notes payable | 50,000 | |||
Debt discounts, net of amortization | (31,149) | $ (5,000) | ||
Accrued coupon interest | 1,876 | |||
Convertible notes payable, gross | 20,727 | |||
April 2019 Convertible Note [Member] | ||||
Principal amount of notes payable | 58,500 | |||
Debt discounts, net of amortization | (27,211) | |||
Accrued coupon interest | 2,859 | |||
Convertible notes payable, gross | 34,148 | |||
2018 Convertible Notes and 2019 Q1 Convertible Notes [Member] | ||||
Principal amount of notes payable | 190,000 | 80,000 | ||
Discount associated with beneficial conversion feature, net of amortization | (27,968) | |||
Accrued interest payable | 13,121 | 401 | ||
Convertible notes payable, gross | 203,121 | 52,433 | ||
Original Convertible Notes [Member] | ||||
Principal amount of notes payable | 125,000 | 125,000 | ||
Accrued interest payable | 76,920 | 62,233 | ||
Convertible notes payable, gross | $ 201,920 | $ 187,233 |
Notes Payable - Schedule of C_2
Notes Payable - Schedule of Convertible Notes Payable (Details) (Parenthetical) - USD ($) | 9 Months Ended | 12 Months Ended | |
Sep. 30, 2019 | Sep. 30, 2018 | Dec. 31, 2018 | |
Amortization of debt discount | $ 119,793 | ||
August 2019 Convertible Note [Member] | |||
Amortization of debt discount | 8,504 | ||
May 2019 Convertible Note [Member] | |||
Amortization of debt discount | 19,072 | ||
April 2019 Convertible Note [Member] | |||
Amortization of debt discount | 21,238 | ||
2018 Convertible Notes and 2019 Q1 Convertible Notes [Member] | |||
Amortization of discount associated with warrant | $ 82,159 | $ 8,379 |
Notes Payable - Summary of Note
Notes Payable - Summary of Note Payable to Related Party (Details) - USD ($) | Sep. 30, 2019 | Dec. 31, 2018 |
Accrued interest payable | $ 17,406 | $ 13,292 |
Total note payable | 723,187 | 744,441 |
SY Corporation [Member] | ||
Principal amount of note payable | 399,774 | 399,774 |
Accrued interest payable | 351,188 | 315,307 |
Foreign currency transaction adjustment | (27,775) | 29,360 |
Total note payable | $ 723,187 | $ 744,441 |
Settlement and Payment Agreem_2
Settlement and Payment Agreements (Details Narrative) - Salamandra, LLC [Member] - USD ($) | Nov. 30, 2019 | Sep. 23, 2019 | Sep. 30, 2019 |
Due to related party | $ 202,395 | ||
Debt settlement description | The agreement in principal calls for a payment of a minimum of $100,000 on or before November 30, 2019 assuming the Company has raised at least $600,000 by that date and thereafter calls for a payment of $50,000 per month until paid in full. If the Company does not make a scheduled payment, the agreement in principal would be deemed null and void. | The settlement agreement reduces the amount owed to a lump-sum payment of $125,000 payable by November 30, 2019, if by that date, the Company has raised an aggregate of at least $600,000 in working capital. Should the Company raise less than $600,000, the Company may pay 21% of the amount raised and cancel that portion of the debt. If the Company is unable to raise $600,000 by November 30, 2019, the settlement agreement becomes null and void. Upon receipt of the settlement payment, mutual releases will become effective with respect to the remaining amount of debt on that date. | |
Working capital | $ 202,400 | ||
Forecast [Member] | |||
Repayment of debt | $ 125,000 | ||
On or Before November 30, 2019 [Member] | |||
Debt periodic payment | $ 100,000 | ||
Thereafter [Member] | |||
Debt periodic payment | $ 50,000 |
Stockholders' Deficiency (Detai
Stockholders' Deficiency (Details Narrative) - USD ($) | Sep. 30, 2019 | Dec. 28, 2018 | Dec. 09, 2017 | Jan. 17, 2017 | Mar. 31, 2016 | Aug. 18, 2015 | Jun. 30, 2015 | Mar. 18, 2014 | Sep. 30, 2019 | Sep. 30, 2018 | Dec. 31, 2018 |
Preferred stock, shares authorized | 5,000,000 | 5,000,000 | |||||||||
Preferred stock, par value | $ 0.001 | $ 0.001 | |||||||||
Preferred stock voting | Cumulative Convertible Preferred Stock (non-voting, "9% Preferred Stock") | ||||||||||
Preferred stock, shares undesignated | 3,505,800 | 3,505,800 | 3,505,800 | ||||||||
Common stock, shares outstanding | 3,879,576 | 3,879,576 | 3,872,076 | ||||||||
Common stock reserved for future issuances | 6,534,657 | 6,534,657 | |||||||||
Common stock reserved for exercises of stock purchase options granted and warrants issued | 6,303,652 | 6,303,652 | |||||||||
Number of shares available for future issuances | 43,452,954 | 43,452,954 | |||||||||
Number of options and restricted stock granted during period | 327,150 | ||||||||||
Stock option period | 4 years 6 months | ||||||||||
Common stock, shares authorized | 65,000,000 | 65,000,000 | 65,000,000 | ||||||||
Common stock, shares issued | 3,879,576 | 3,879,576 | 3,872,076 | ||||||||
2014 Equity Plan [Member] | |||||||||||
Number of options and restricted stock granted during period | 325,025 | ||||||||||
2015 Stock and Stock Option Plan [Member] | Board of Directors [Member] | |||||||||||
Option issued to purchase number of common stock | 461,538 | ||||||||||
Stock option period | 10 years | ||||||||||
2015 Equity Plan [Member] | |||||||||||
Fair value of market price per share | $ 0.45 | $ 0.45 | $ 0.7101 | ||||||||
Stock warrant intrinsic value of exercisable | |||||||||||
Deferred compensation expense | |||||||||||
2015 Equity Plan [Member] | Board of Directors [Member] | |||||||||||
Number of options and restricted stock granted during period | 8,985,260 | 6,985,260 | 3,038,461 | 1,538,461 | 769,231 | ||||||
2015 Stock and Stock Option Plan [Member] | Board of Directors [Member] | |||||||||||
Number of options and restricted stock granted during period | 1,500,000 | ||||||||||
2015 Stock and Stock Option Plan [Member] | Board of Directors [Member] | Minimum [Member] | |||||||||||
Number of options and restricted stock granted during period | 1,538,461 | ||||||||||
2015 Stock and Stock Option Plan [Member] | Board of Directors [Member] | Maximum [Member] | |||||||||||
Number of options and restricted stock granted during period | 3,038,461 | ||||||||||
2015 Stock and Stock Option Plan [Member] | Board of Directors [Member] | |||||||||||
Common stock reserved for future issuances | 4,490,578 | 4,490,578 | |||||||||
Number of shares available for future issuances | 42,918,394 | 42,918,394 | |||||||||
Number of options and restricted stock granted during period | 8,985,260 | 6,985,260 | |||||||||
Common stock, shares authorized | 65,000,000 | 65,000,000 | |||||||||
Common stock, shares issued | 3,879,576 | 3,879,576 | |||||||||
2014 and 2015 Plans [Member] | |||||||||||
Common stock reserved for future issuances | 4,490,578 | 4,490,578 | |||||||||
Conversions of Convertible Debt [Member] | |||||||||||
Common stock reserved for future issuances | 7,401,292 | 7,401,292 | |||||||||
Conversions of Convertible Debt [Member] | 2015 Stock and Stock Option Plan [Member] | Board of Directors [Member] | |||||||||||
Common stock reserved for future issuances | 7,401,292 | 7,401,292 | |||||||||
Series B Convertible Preferred Stock [Member] | |||||||||||
Preferred stock, shares authorized | 37,500 | 37,500 | 37,500 | ||||||||
Preferred stock, par value | $ 0.001 | $ 0.001 | $ 0.001 | ||||||||
Preferred stock shares issuable upon conversion, per share | 0.00030 | 0.00030 | $ 0.00030 | $ 0.00030 | |||||||
Debt instrument, conversion price per share | $ 2,208.375 | $ 2,208.375 | 2,208.375 | ||||||||
Preferred stock shares issuable upon conversion | 11 | 11 | 11 | ||||||||
Preferred stock redemption amount | $ 25,001 | $ 25,001 | $ 25,001 | ||||||||
Redeemed preferred stock price per share | $ 0.6667 | $ 0.6667 | $ 0.6667 | ||||||||
Series B Convertible Preferred Stock [Member] | 2015 Stock and Stock Option Plan [Member] | Board of Directors [Member] | |||||||||||
Common stock shares issuable upon conversion | 11 | ||||||||||
Series A Junior Participating Preferred Stock [Member] | |||||||||||
Preferred stock, shares designated | 205,000 | 205,000 | 205,000 | ||||||||
Series G 1.5% Convertible Preferred Stock [Member] | |||||||||||
Preferred stock, shares designated | 1,700 | 1,700 | 1,700 | ||||||||
9% Cumulative Convertible Preferred Stock [Member] | |||||||||||
Preferred stock, shares authorized | 1,250,000 | 1,250,000 | 1,250,000 | ||||||||
Common Stock [Member] | |||||||||||
Common stock reserved for future issuances | 7,383,482 | 7,383,482 | |||||||||
Common Stock [Member] | 2015 Stock and Stock Option Plan [Member] | Board of Directors [Member] | |||||||||||
Common stock reserved for future issuances | 7,383,482 | 7,383,482 | |||||||||
Pier Contingent Shares [Member] | |||||||||||
Common stock reserved for future issuances | 6,497 | 6,497 | |||||||||
Pier Contingent Shares [Member] | 2015 Stock and Stock Option Plan [Member] | Board of Directors [Member] | |||||||||||
Common stock reserved for future issuances | 6,497 | 6,497 | |||||||||
Common Stock Warrants [Member] | |||||||||||
Fair value of market price per share | $ 0.45 | $ 0.45 | $ 0.7171 | ||||||||
Stock warrant intrinsic value of exercisable | $ 7,500 | $ 7,500 | |||||||||
Common Stock One [Member] | 2015 Stock and Stock Option Plan [Member] | Board of Directors [Member] | |||||||||||
Common stock reserved for future issuances | 6,516,847 | 6,516,847 |
Stockholders' Deficiency - Sche
Stockholders' Deficiency - Schedule of Warrants Activity (Details) - $ / shares | 9 Months Ended | |
Sep. 30, 2019 | Sep. 30, 2018 | |
Equity [Abstract] | ||
Number of Warrants, Outstanding, Beginning balance | 1,783,229 | 1,464,415 |
Number of Warrants, Issued | 302,372 | 238,814 |
Number of Warrants, Expired | (69,558) | |
Number of Warrants, Outstanding, Ending balance | 2,016,043 | 1,703,229 |
Weighted Average Exercise Price, Outstanding, Beginning | $ 2.20393 | $ 2.68146 |
Weighted Average Exercise Price, Issued | 0.95908 | 1.57500 |
Weighted Average Exercise Price, Expired | 2.65928 | |
Weighted Average Exercise Price, Outstanding, Ending | $ 1.99011 | $ 2.52632 |
Warrants outstanding ,Weighted Average Remaining Contractual Life (in Years), Beginning | 3 years 22 days | 3 years 8 months 23 days |
Warrants outstanding ,Weighted Average Remaining Contractual Life (in Years), Ending | 2 years 8 months 23 days | 4 years 29 days |
Number of Warrants, Exercisable, Beginning balance | 1,783,229 | 1,464,415 |
Number of Warrants, Exercisable, Ending balance | 2,016,043 | 1,703,229 |
Weighted Average Exercise Price, Exercisable, Beginning | $ 2.20393 | $ 2.68146 |
Weighted Average Exercise Price, Exercisable, Ending | $ 1.99011 | $ 2.52632 |
Warrants exercisable, Weighted Average Remaining Contractual Life (in Years), Beginning | 3 years 22 days | 3 years 8 months 23 days |
Warrants exercisable, Weighted Average Remaining Contractual Life (in Years), Ending | 2 years 8 months 23 days | 4 years 29 days |
Stockholders' Deficiency - Summ
Stockholders' Deficiency - Summary of Stock Option Activity (Details) - $ / shares | 9 Months Ended | |
Sep. 30, 2019 | Sep. 30, 2018 | |
Equity [Abstract] | ||
Number of shares, Options outstanding, beginning balance | 4,344,994 | 3,996,167 |
Number of shares, Options Expired | (57,385) | |
Number of shares, Options Granted | 327,150 | |
Number of shares, Options outstanding, ending balance | 4,287,609 | 4,323,317 |
Weighted Average Exercise Price, Options outstanding, beginning balance | $ 3.7634 | $ 3.7634 |
Weighted Average Exercise Price, Options Expired | (15.6139) | |
Weighted Average Exercise Price, Options Granted | 1.1267 | |
Weighted Average Exercise Price, Options outstanding, ending balance | $ 3.3798 | $ 3.5855 |
Weighted Average Remaining Contractual Life (in Years), Options outstanding, beginning balance | 7 years 4 months 17 days | 6 years 3 months 19 days |
Weighted Average Remaining Contractual Life (in Years), Options Granted | 4 years 6 months | |
Weighted Average Remaining Contractual Life (in Years), Options outstanding, ending balance | 5 years 2 months 23 days | 6 years 2 months 1 day |
Number of shares, Options exercisable beginning balance | 4,344,994 | 3,996,167 |
Number of shares, Options exercisable ending balance | 4,287,609 | 4,323,317 |
Weighted Average Exercise Price, Options exercisable beginning balance | $ 3.7634 | $ 3.7634 |
Weighted Average Exercise Price, Options exercisable ending balance | $ 3.3798 | $ 3.5855 |
Weighted Average Remaining Contractual Life (in Years), Options exercisable beginning balance | 7 years 4 months 17 days | 6 years 3 months 19 days |
Weighted Average Remaining Contractual Life (in Years), Options exercisable ending balance | 5 years 2 months 23 days | 6 years 2 months 1 day |
Stockholders' Deficiency - Sc_2
Stockholders' Deficiency - Schedule of Exercise Prices of Common Stock Warrants Outstanding and Exercisable (Details) - $ / shares | Sep. 30, 2019 | Dec. 31, 2018 | Sep. 30, 2018 | Dec. 31, 2017 |
Warrants, Outstanding (Shares) | 2,016,043 | 1,783,229 | 1,703,229 | 1,464,415 |
Warrants, Exercisable (Shares) | 2,016,043 | 1,783,229 | 1,703,229 | 1,464,415 |
Warrants [Member] | ||||
Warrants, Outstanding (Shares) | 2,016,043 | 1,703,229 | ||
Warrants, Exercisable (Shares) | 2,016,043 | 1,703,229 | ||
Exercise Price Range One [Member] | Warrants [Member] | ||||
Warrants, Exercise Price | $ 0.5000 | $ 1 | ||
Warrants, Outstanding (Shares) | 150,000 | 916,217 | ||
Warrants, Exercisable (Shares) | 150,000 | 916,217 | ||
Warrants, Expiration Date | Aug. 19, 2024 | Sep. 20, 2022 | ||
Exercise Price Range Two [Member] | Warrants [Member] | ||||
Warrants, Exercise Price | $ 1 | $ 1.2870 | ||
Warrants, Outstanding (Shares) | 916,217 | 41,002 | ||
Warrants, Exercisable (Shares) | 916,217 | 41,002 | ||
Warrants, Expiration Date | Sep. 20, 2022 | Apr. 17, 2019 | ||
Exercise Price Range Three [Member] | Warrants [Member] | ||||
Warrants, Exercise Price | $ 1.1800 | $ 1.5620 | ||
Warrants, Outstanding (Shares) | 42,372 | 130,284 | ||
Warrants, Exercisable (Shares) | 42,372 | 130,284 | ||
Warrants, Expiration Date | May 17, 2022 | Dec. 31, 2021 | ||
Exercise Price Range Four [Member] | Warrants [Member] | ||||
Warrants, Exercise Price | $ 1.5000 | $ 1.5750 | ||
Warrants, Outstanding (Shares) | 190,000 | 238,814 | ||
Warrants, Exercisable (Shares) | 190,000 | 238,814 | ||
Warrants, Expiration Date | Dec. 30, 2023 | Apr. 30, 2023 | ||
Exercise Price Range Five [Member] | Warrants [Member] | ||||
Warrants, Exercise Price | $ 1.5620 | $ 2.7500 | ||
Warrants, Outstanding (Shares) | 130,284 | 8,000 | ||
Warrants, Exercisable (Shares) | 130,284 | 8,000 | ||
Warrants, Expiration Date | Dec. 31, 2021 | Sep. 20, 2022 | ||
Exercise Price Range Six [Member] | Warrants [Member] | ||||
Warrants, Exercise Price | $ 1.5750 | $ 4.8500 | ||
Warrants, Outstanding (Shares) | 238,814 | 5,155 | ||
Warrants, Exercisable (Shares) | 238,814 | 5,155 | ||
Warrants, Expiration Date | Apr. 30, 2023 | Sep. 23, 2019 | ||
Exercise Price Range Seven [Member] | Warrants [Member] | ||||
Warrants, Exercise Price | $ 2.7500 | $ 4.8750 | ||
Warrants, Outstanding (Shares) | 8,000 | 108,594 | ||
Warrants, Exercisable (Shares) | 8,000 | 108,594 | ||
Warrants, Expiration Date | Sep. 20, 2022 | Sep. 30, 2020 | ||
Exercise Price Range Eight [Member] | Warrants [Member] | ||||
Warrants, Exercise Price | $ 4.8750 | $ 5 | ||
Warrants, Outstanding (Shares) | 108,594 | 5,000 | ||
Warrants, Exercisable (Shares) | 108,594 | 5,000 | ||
Warrants, Expiration Date | Sep. 30, 2020 | Sep. 22, 2019 | ||
Exercise Price Range Nine [Member] | Warrants [Member] | ||||
Warrants, Exercise Price | $ 6.8348 | $ 5.1025 | ||
Warrants, Outstanding (Shares) | 145,758 | 10,309 | ||
Warrants, Exercisable (Shares) | 145,758 | 10,309 | ||
Warrants, Expiration Date | Sep. 30, 2020 | Jan. 29, 2019 | ||
Exercise Price Range Ten [Member] | Warrants [Member] | ||||
Warrants, Exercise Price | $ 7.9300 | $ 6.5000 | ||
Warrants, Outstanding (Shares) | 86,004 | 8,092 | ||
Warrants, Exercisable (Shares) | 86,004 | 8,092 | ||
Warrants, Expiration Date | Feb. 28, 2021 | Feb. 4, 2019 | ||
Exercise Price Range Eleven [Member] | Warrants [Member] | ||||
Warrants, Exercise Price | $ 6.8348 | |||
Warrants, Outstanding (Shares) | 145,758 | |||
Warrants, Exercisable (Shares) | 145,758 | |||
Warrants, Expiration Date | Sep. 30, 2020 | |||
Exercise Price Range Twelve [Member] | Warrants [Member] | ||||
Warrants, Exercise Price | $ 7.9300 | |||
Warrants, Outstanding (Shares) | 86,004 | |||
Warrants, Exercisable (Shares) | 86,004 | |||
Warrants, Expiration Date | Feb. 28, 2021 |
Stockholders' Deficiency - Sc_3
Stockholders' Deficiency - Schedule of Exercise Prices of Common Stock Options Outstanding and Exercisable (Details) - $ / shares | 9 Months Ended | |||
Sep. 30, 2019 | Sep. 30, 2018 | Dec. 31, 2018 | Dec. 31, 2017 | |
Options Outstanding (Shares) | 4,287,609 | 4,323,317 | 4,344,994 | 3,996,167 |
Options Exercisable (Shares) | 4,287,609 | 4,323,317 | 4,344,994 | 3,996,167 |
Stock Option One [Member] | ||||
Options Exercise Price | $ 0.7000 | $ 1.1200 | ||
Options Outstanding (Shares) | 21,677 | 310,388 | ||
Options Exercisable (Shares) | 21,677 | 310,388 | ||
Options, Expiration Date | Nov. 21, 2023 | Apr. 5, 2023 | ||
Stock Option Two [Member] | ||||
Options Exercise Price | $ 1.1200 | $ 1.2500 | ||
Options Outstanding (Shares) | 310,388 | 16,762 | ||
Options Exercisable (Shares) | 310,388 | 16,762 | ||
Options, Expiration Date | Apr. 5, 2023 | Dec. 7, 2022 | ||
Stock Option Three [Member] | ||||
Options Exercise Price | $ 1.2500 | $ 1.3500 | ||
Options Outstanding (Shares) | 16,762 | 34,000 | ||
Options Exercisable (Shares) | 16,762 | 34,000 | ||
Options, Expiration Date | Dec. 7, 2022 | Jul. 28, 2022 | ||
Stock Option Four [Member] | ||||
Options Exercise Price | $ 1.3500 | $ 1.4500 | ||
Options Outstanding (Shares) | 34,000 | 1,849,418 | ||
Options Exercisable (Shares) | 34,000 | 1,849,418 | ||
Options, Expiration Date | Jul. 28, 2022 | Dec. 9, 2027 | ||
Stock Option Five [Member] | ||||
Options Exercise Price | $ 1.4500 | $ 1.4500 | ||
Options Outstanding (Shares) | 1,849,418 | 100,000 | ||
Options Exercisable (Shares) | 1,849,418 | 100,000 | ||
Options, Expiration Date | Dec. 9, 2027 | Dec. 9, 2027 | ||
Stock Option Six [Member] | ||||
Options Exercise Price | $ 1.4500 | $ 2 | ||
Options Outstanding (Shares) | 100,000 | 285,000 | ||
Options Exercisable (Shares) | 100,000 | 285,000 | ||
Options, Expiration Date | Dec. 9, 2027 | Jun. 30, 2022 | ||
Stock Option Seven [Member] | ||||
Options Exercise Price | $ 2 | $ 2 | ||
Options Outstanding (Shares) | 285,000 | 25,000 | ||
Options Exercisable (Shares) | 285,000 | 25,000 | ||
Options, Expiration Date | Jun. 30, 2022 | Jul. 26, 2022 | ||
Stock Option Eight [Member] | ||||
Options Exercise Price | $ 2 | $ 3.9000 | ||
Options Outstanding (Shares) | 25,000 | 395,000 | ||
Options Exercisable (Shares) | 25,000 | 395,000 | ||
Options, Expiration Date | Jul. 26, 2022 | Jan. 17, 2022 | ||
Stock Option Nine [Member] | ||||
Options Exercise Price | $ 3.9000 | $ 4.5000 | ||
Options Outstanding (Shares) | 395,000 | 7,222 | ||
Options Exercisable (Shares) | 395,000 | 7,222 | ||
Options, Expiration Date | Jan. 17, 2022 | Sep. 2, 2021 | ||
Stock Option Ten [Member] | ||||
Options Exercise Price | $ 4.5000 | $ 5.6875 | ||
Options Outstanding (Shares) | 7,222 | 89,686 | ||
Options Exercisable (Shares) | 7,222 | 89,686 | ||
Options, Expiration Date | Sep. 2, 2021 | Jun. 30, 2020 | ||
Stock Option Eleven [Member] | ||||
Options Exercise Price | $ 5.6875 | $ 5.7500 | ||
Options Outstanding (Shares) | 89,686 | 2,608 | ||
Options Exercisable (Shares) | 89,686 | 2,608 | ||
Options, Expiration Date | Jun. 30, 2020 | Sep. 12, 2021 | ||
Stock Option Twelve[Member] | ||||
Options Exercise Price | $ 5.7500 | $ 6.4025 | ||
Options Outstanding (Shares) | 2,608 | 27,692 | ||
Options Exercisable (Shares) | 2,608 | 27,692 | ||
Options, Expiration Date | Sep. 12, 2021 | Aug. 18, 2020 | ||
Stock Option Thirteen [Member] | ||||
Options Exercise Price | $ 6.4025 | $ 6.4025 | ||
Options Outstanding (Shares) | 27,692 | 129,231 | ||
Options Exercisable (Shares) | 27,692 | 129,231 | ||
Options, Expiration Date | Aug. 18, 2020 | Aug. 18, 2022 | ||
Stock Option Fourteen [Member] | ||||
Options Exercise Price | $ 6.4025 | $ 6.4025 | ||
Options Outstanding (Shares) | 129,231 | 261,789 | ||
Options Exercisable (Shares) | 129,231 | 261,789 | ||
Options, Expiration Date | Aug. 18, 2022 | Aug. 18, 2025 | ||
Stock Option Fifteen [Member] | ||||
Options Exercise Price | $ 6.4025 | $ 6.8250 | ||
Options Outstanding (Shares) | 261,789 | 8,791 | ||
Options Exercisable (Shares) | 261,789 | 8,791 | ||
Options, Expiration Date | Aug. 18, 2025 | Dec. 11, 2020 | ||
Stock Option Sixteen [Member] | ||||
Options Exercise Price | $ 6.8250 | $ 7.3775 | ||
Options Outstanding (Shares) | 8,791 | 523,077 | ||
Options Exercisable (Shares) | 8,791 | 523,077 | ||
Options, Expiration Date | Dec. 11, 2020 | Mar. 31, 2021 | ||
Stock Option Seventeen [Member] | ||||
Options Exercise Price | $ 7.3775 | $ 8.1250 | ||
Options Outstanding (Shares) | 523,077 | 169,231 | ||
Options Exercisable (Shares) | 523,077 | 169,231 | ||
Options, Expiration Date | Mar. 31, 2021 | Jun. 30, 2022 | ||
Stock Option Eighteen [Member] | ||||
Options Exercise Price | $ 8.1250 | $ 13 | ||
Options Outstanding (Shares) | 169,231 | 7,385 | ||
Options Exercisable (Shares) | 169,231 | 7,385 | ||
Options, Expiration Date | Jun. 30, 2022 | Mar. 13, 2019 | ||
Stock Option Nineteen [Member] | ||||
Options Exercise Price | $ 13.9750 | $ 13 | ||
Options Outstanding (Shares) | 3,385 | 3,846 | ||
Options Exercisable (Shares) | 3,385 | 3,846 | ||
Options, Expiration Date | Mar. 14, 2024 | Apr. 14, 2019 | ||
Stock Option Twenty [Member] | ||||
Options Exercise Price | $ 15.4700 | $ 13.9750 | ||
Options Outstanding (Shares) | 7,755 | 3,385 | ||
Options Exercisable (Shares) | 7,755 | 3,385 | ||
Options, Expiration Date | Apr. 8, 2020 | Mar. 14, 2024 | ||
Stock Option Twenty One [Member] | ||||
Options Exercise Price | $ 15.9250 | $ 15.4700 | ||
Options Outstanding (Shares) | 2,462 | 7,755 | ||
Options Exercisable (Shares) | 2,462 | 7,755 | ||
Options, Expiration Date | Feb. 28, 2024 | Apr. 8, 2020 | ||
Stock Option Twenty Two [Member] | ||||
Options Exercise Price | $ 16.6400 | $ 15.9250 | ||
Options Outstanding (Shares) | 1,538 | 2,462 | ||
Options Exercisable (Shares) | 1,538 | 2,462 | ||
Options, Expiration Date | Jan. 29, 2020 | Feb. 28, 2024 | ||
Stock Option Twenty Three [Member] | ||||
Options Exercise Price | $ 19.5000 | $ 16.0500 | ||
Options Outstanding (Shares) | 9,487 | 46,154 | ||
Options Exercisable (Shares) | 9,487 | 46,154 | ||
Options, Expiration Date | Jul. 17, 2022 | Jul. 17, 2019 | ||
Stock Option Twenty Four [Member] | ||||
Options Exercise Price | $ 19.5000 | $ 16.6400 | ||
Options Outstanding (Shares) | 6,410 | 1,538 | ||
Options Exercisable (Shares) | 6,410 | 1,538 | ||
Options, Expiration Date | Aug. 10, 2022 | Jan. 29, 2020 | ||
Stock Option Twenty Five [Member] | ||||
Options Exercise Price | $ 19.5000 | |||
Options Outstanding (Shares) | 9,487 | |||
Options Exercisable (Shares) | 9,487 | |||
Options, Expiration Date | Jul. 17, 2022 | |||
Stock Option Twenty Six [Member] | ||||
Options Exercise Price | $ 19.5000 | |||
Options Outstanding (Shares) | 6,410 | |||
Options Exercisable (Shares) | 6,410 | |||
Options, Expiration Date | Aug. 10, 2022 |
Commitments and Contingencies_2
Commitments and Contingencies (Details Narrative) | Jul. 21, 2016USD ($) | Jan. 12, 2016USD ($) | Jan. 12, 2016CAD ($) | Sep. 30, 2015USD ($) | Aug. 18, 2015USD ($)shares | Oct. 15, 2014USD ($) | Jun. 27, 2014USD ($) | Sep. 30, 2019USD ($)shares | Sep. 30, 2018USD ($)shares | Jun. 30, 2018USD ($) | Sep. 30, 2019USD ($)shares | Sep. 30, 2018USD ($)shares | Dec. 31, 2018USD ($)shares | Jan. 31, 2018USD ($) | Jan. 31, 2018CAD ($) | Dec. 31, 2017shares |
Due and payable investment banking services | $ 225,000 | |||||||||||||||
Cash fee | $ 5,000 | |||||||||||||||
Stock options to purchase | shares | 4,287,609 | 4,323,317 | 4,287,609 | 4,323,317 | 4,344,994 | 3,996,167 | ||||||||||
Principal cash obligations and commitments | $ 1,211,200 | $ 1,211,200 | ||||||||||||||
Dr. Arnold S.Lippa [Member] | ||||||||||||||||
Cash compensation expense | 84,900 | $ 84,900 | 254,700 | $ 254,700 | $ 339,600 | |||||||||||
Stock options to purchase | shares | 30,769 | |||||||||||||||
Health plan for employees expense | $ 1,200 | |||||||||||||||
Maximum health coverage amount per month | $ 1,000 | |||||||||||||||
Percentage of annual bonus from base salary | 50.00% | |||||||||||||||
Base salary | $ 300,000 | |||||||||||||||
Mr Margolis [Member] | ||||||||||||||||
Stock options to purchase | shares | 30,769 | |||||||||||||||
Health plan for employees expense | $ 1,200 | |||||||||||||||
Maximum health coverage amount per month | 1,000 | |||||||||||||||
Base salary | 300,000 | |||||||||||||||
Dr. Manuso, Dr. Lippa, Mr. Margolis and Mr. Weingarten [Member] | ||||||||||||||||
Net proceeds from offering cost | 2,000,000 | |||||||||||||||
Minimum [Member] | Mr Margolis [Member] | ||||||||||||||||
Bonuses | 65,000 | |||||||||||||||
Maximum [Member] | Mr Margolis [Member] | ||||||||||||||||
Bonuses | $ 125,000 | |||||||||||||||
Consulting Agreement [Member] | DNA Healthlink, Inc [Member] | Richard Purcell [Member] | ||||||||||||||||
Cash fee | $ 12,500 | |||||||||||||||
Cash compensation expense | 37,500 | 37,500 | 112,500 | 112,500 | ||||||||||||
Employment Agreements [Member] | Tranche One [Member] | ||||||||||||||||
Cash bonuses | $ 15,000 | |||||||||||||||
Excess of financing cost | 100,000 | |||||||||||||||
Employment Agreements [Member] | Tranche Two [Member] | ||||||||||||||||
Cash bonuses | 15,000 | |||||||||||||||
Excess of financing cost | 200,000 | |||||||||||||||
Employment Agreements [Member] | Tranche Three [Member] | ||||||||||||||||
Cash bonuses | 30,000 | |||||||||||||||
Excess of financing cost | 250,000 | |||||||||||||||
Employment Agreements [Member] | Jeff E. Margolis [Member] | ||||||||||||||||
Cash bonuses | 60,000 | |||||||||||||||
Employment Agreements [Member] | Minimum [Member] | Jeff E. Margolis [Member] | ||||||||||||||||
Cash bonuses | $ 15,000 | |||||||||||||||
Recurring Cash Compensation Accrued Pursuant Amended Agreement [Member] | ||||||||||||||||
Cash compensation expense | 80,400 | 80,400 | $ 241,200 | $ 241,200 | $ 321,600 | |||||||||||
University of Illinois 2014 Exclusive License Agreement [Member] | ||||||||||||||||
License agreement effective date | Sep. 18, 2014 | |||||||||||||||
License fee | $ 25,000 | |||||||||||||||
Outstanding patent costs | $ 15,840 | |||||||||||||||
Percentage of royalty on net sale | 4.00% | |||||||||||||||
Percentage of payment on sub licensee revenue | 12.50% | |||||||||||||||
Minimum annual royalty payment amount | $ 100,000 | |||||||||||||||
Royalty due date | Feb. 28, 2019 | |||||||||||||||
Charge to operations with royalty obligation | $ 25,000 | $ 25,000 | $ 75,000 | $ 75,000 | ||||||||||||
University of Illinois 2014 Exclusive License Agreement [Member] | Research and Development Expenses [Member] | ||||||||||||||||
Minimum annual royalty payment amount | 150,000 | |||||||||||||||
University of Illinois 2014 Exclusive License Agreement [Member] | Due Within Five Days After Dosing of First Patient Phase Three Human Clinical Trial [Member] | ||||||||||||||||
Payment for sale of product | 350,000 | |||||||||||||||
University of Illinois 2014 Exclusive License Agreement [Member] | Due Within Five Days After First New Drug Application Filing [Member] | ||||||||||||||||
Payment for sale of product | 500,000 | |||||||||||||||
University of Illinois 2014 Exclusive License Agreement [Member] | Due Within Twelve Months of First Commercial Sale Member [Member] | ||||||||||||||||
Payment for sale of product | 1,000,000 | |||||||||||||||
University of Illinois 2014 Exclusive License Agreement [Member] | Maximum [Member] | First Sale Of Product [Member] | ||||||||||||||||
Minimum annual royalty payment amount | 200,000 | |||||||||||||||
University of Illinois 2014 Exclusive License Agreement [Member] | Maximum [Member] | First Commercial Sale Of Product [Member] | ||||||||||||||||
Minimum annual royalty payment amount | $ 250,000 | |||||||||||||||
Neuroscience and Mental Health Institute at University of Alberta [Member] | ||||||||||||||||
Research grants award amount | $ 111,000 | |||||||||||||||
Additional cost budgeted under research grant | 65,000 | |||||||||||||||
Funding cash installments | 16,000 | |||||||||||||||
Payments to patent costs | 15,000 | |||||||||||||||
Underwrite additional budgeted costs | $ 15,000 | |||||||||||||||
Accounts payable | $ 16,207 | |||||||||||||||
Foreign conversion exchange rate | 0.76 | 0.76 | ||||||||||||||
Neuroscience and Mental Health Institute at University of Alberta [Member] | CAD [Member] | ||||||||||||||||
Research grants award amount | $ 146,000 | |||||||||||||||
Additional cost budgeted under research grant | 85,000 | |||||||||||||||
Funding cash installments | 21,000 | |||||||||||||||
Payments to patent costs | 20,000 | |||||||||||||||
Underwrite additional budgeted costs | $ 20,000 | |||||||||||||||
Accounts payable | $ 21,222 | |||||||||||||||
Foreign conversion exchange rate | 1 | 1 |
Commitments and Contingencies -
Commitments and Contingencies - Summary of Principal Cash Obligations and Commitments (Details) | Sep. 30, 2019USD ($) | |
2019 | $ 315,300 | |
2020 | 595,900 | |
2021 | 100,000 | |
2022 | 100,000 | |
2023 | 100,000 | |
Total | 1,211,200 | |
License Agreements [Member] | ||
2019 | 25,000 | |
2020 | 100,000 | |
2021 | 100,000 | |
2022 | 100,000 | |
2023 | 100,000 | |
Total | 425,000 | |
Litigation Settlement [Member] | ||
2019 | 125,000 | |
2020 | ||
2021 | ||
2022 | ||
2023 | ||
Total | 125,000 | |
Employment Agreements [Member] | ||
2019 | 165,300 | [1] |
2020 | 495,900 | [1] |
2021 | [1] | |
2022 | [1] | |
2023 | [1] | |
Total | $ 661,200 | [1] |
[1] | The payment of such amounts has been deferred indefinitely, as described above at "Employment Agreements." The 2019 amounts include three months of employment agreement obligations for Dr. Lippa and Mr. Margolis as their employment contracts renewed on September 30, 2018 and the 2019 obligations include the three months of obligations through December 31, 2019 |
Subsequent Events (Details Narr
Subsequent Events (Details Narrative) | Nov. 12, 2019USD ($)$ / sharesshares | Nov. 04, 2019USD ($)TradingDaysshares | Oct. 28, 2019USD ($)$ / sharesshares | Oct. 22, 2019USD ($)TradingDays$ / sharesshares | Apr. 24, 2019USD ($)$ / sharesshares | Jun. 25, 2012 | Sep. 30, 2019USD ($)shares | Dec. 31, 2018USD ($) | Sep. 30, 2018 |
Debt instrument interest rate | 10.00% | ||||||||
Debt maturity date | Jun. 25, 2013 | ||||||||
Debt instrument original issue discount | $ 104,858 | $ 27,969 | |||||||
Number of shares reserved | shares | 6,534,657 | ||||||||
April 2019 Convertible Note [Member] | |||||||||
Debt instrument interest rate | 10.00% | ||||||||
Debt maturity date | Apr. 24, 2020 | ||||||||
Proceeds from convertible debt | $ 50,000 | ||||||||
Debt face amount | $ 58,500 | ||||||||
Debt instrument original issue discount | $ 27,211 | ||||||||
Debt converted into shares | shares | 147,541 | ||||||||
Debt instrument, convertible, conversion price | $ / shares | $ 0.3964 | ||||||||
Subsequent Event [Member] | October 2019 Convertible Note [Member] | |||||||||
Debt instrument interest rate | 10.00% | ||||||||
Debt maturity date | Jul. 22, 2020 | ||||||||
Proceeds from convertible debt | $ 54,500 | ||||||||
Debt face amount | 60,000 | ||||||||
Debt instrument original issue discount | 1,750 | ||||||||
Capitalized note costs | $ 3,750 | ||||||||
Number of restricted shares issued | shares | 10,000 | ||||||||
Warrant to purchase shares | shares | 175,000 | ||||||||
Warrant exercise price | $ / shares | $ 0.50 | ||||||||
Warrant term | 5 years | ||||||||
Debt instrument, consecutive trading days | TradingDays | 20 | ||||||||
Number of shares reserved | shares | 1,935,000 | ||||||||
Subsequent Event [Member] | November 2019 Convertible Note [Member] | |||||||||
Debt instrument interest rate | 10.00% | ||||||||
Debt maturity date | Nov. 4, 2020 | ||||||||
Proceeds from convertible debt | $ 147,900 | ||||||||
Debt face amount | 170,000 | ||||||||
Debt instrument original issue discount | 13,600 | ||||||||
Capitalized note costs | $ 8,500 | ||||||||
Warrant to purchase shares | shares | |||||||||
Debt instrument, description | The November 2019 Convertible Note may be prepaid subject to prepayment premium factors as described in the definitive documents and may not be prepaid after the 180th day. The holder may convert, at any time, the November 2019 Convertible Note at the holder's option into shares of the Company's common stock at a price that is 60% of the lowest trading price, taking into consideration only trades of 100 shares or more, for the twenty (20) consecutive trading days prior to and inclusive of the conversion date of such conversion. | ||||||||
Debt instrument, consecutive trading days | TradingDays | 20 | ||||||||
Number of shares reserved | shares | 5,200,000 | ||||||||
Subsequent Event [Member] | April 2019 Convertible Note [Member] | |||||||||
Debt converted into share, value | $ 10,000 | $ 10,000 | |||||||
Debt converted into shares | shares | 81,967 | 73,529 | |||||||
Debt instrument, convertible, conversion price | $ / shares | $ 0.1220 | $ 0.1360 | |||||||
Convertible notes payable | $ 38,500 |